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Nasopharyngeal Carcinoma (NPC) is the 6th most common cancer in Singapore 
males with a striking geographical and ethnic distribution. The molecular basis 
of NPC development is still poorly understood, but a strong linkage to the 
Epstein-Barr virus (EBV) has been shown. Other contributing factors include 
various genetic, epigenetic and environmental factors which together drive the 
development of this tumor. The identification of tumor suppressor genes (TSG) 
silenced by promoter DNA methylation uncover mechanisms of tumorigenesis 
and identifies new epigenetic tumor markers for early cancer detection. In this 
thesis we describe our efforts in the elucidation and characterization of novel 
tumor suppressor gene candidates epigenetically silenced via promoter DNA 
hypermethylation and relevant in NPC and multiple other tumors.  
 In our first study, we described the identification and characterization of 
a new DLC1 isoform designated as DLC1-isoform 4 (DLC1-i4). This novel 
isoform encodes an 1125-aa (amino acid) protein with a distinct N-terminus as 
compared with other known DLC1 isoforms. Similar to other isoforms, DLC1-i4 
is expressed ubiquitously in normal tissues and immortalized normal epithelial 
cells, suggesting a role as a major DLC1 transcript. DLC1-i4 is also found to be 
significantly down-regulated in multiple carcinoma cell lines, including 2/4 
nasopharyngeal (50%), 8/16 (50%) esophageal, 4/16 (25%) gastric, 6/9 (67%) 
breast, 3/4 (75%) colorectal, 4/4 cervical (100%) and 2/8 (25%) lung carcinoma 
cell lines. We also found that CpG methylation of the DLC1-i4 promoter is 
associated with its silencing in tumor cells.  
 ix 
 
 In the second study, we described how we identified the Neuronal PAS 
domain protein 4 (NPAS4) as a novel candidate tumor suppressor gene in NPC 
and other tumors. From literature searches, a chromosome 11q13 1.8Mb tumor 
suppressor critical region was identified and predicted to harbour novel tumor 
suppressor gene candidates. It was also predicted that this tumor suppressor 
might play a role in transcriptional regulation. We interrogated the 1.8 Mb 
tumor suppressive region for candidate transcriptional regulators and identified 
NPAS4 as the only one down-regulated by promoter DNA hypermethylation in 
NPC and other tumors. NPAS4 was further found to have tumor inhibitory 
properties and is an indirect target of the known tumor suppressor TP53 after 
DNA damage treatments and thus suggested to play a role in the cellular DNA 
damage response. 
 In summary, we report the characterization of an epigenetics promoter 
DNA methylation silencing mechanism responsible in the down-regulation of 
DLC1-i4 and NPAS4 in NPC and other tumors. The high incidences of 
epigenetic inactivation of these genes in multiple tumor types strongly indicate 
that these genes may serve as potential epigenetic markers for the diagnosis and 
prognosis of tumors.    
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1.1 Introduction to DNA methylation 
A current definition of epigenetics is the study of mitotically and/or meiotically 
heritable changes in gene expression that occur without changes in the DNA 
sequences (Berger et al., 2009; Rodriguez-Paredes and Esteller, 2011). The best 
studied epigenetic regulation is DNA methylation and it will be discussed in this 
review. DNA methylation is a straightforward reaction of catalyzing the transfer 
of a methyl group to a cytosine base in DNA by DNA cytosine-5 
methyltransferase (DNMT) to form 5-methylcytosine (m5C) (Figure 1.1). m5C 
accounts for ~1% of the total DNA bases and affect about 70 – 80% of the total 
CpG dinucleotides in the genome (Ehrlich et al., 1982). DNA methylation is 
important in tissue-specific gene expression throughout development and the 
methylation pattern changes at discrete phases of the cell cycle (Meehan, 2003; 
Plass and Soloway, 2002; Santos et al., 2003)  
 
Figure 1.1. Schematic representation of cytosine methylation catalyzed by 
DNA cytosine-5 methyltransferase. 
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 CpG dinucleotides were observed to be concentrated into GC-rich 
regions called CpG islands (CGIs) and positioned at the 5' promoter region of 
many human genes (Bird, 1986). Computational analysis by two different 
groups estimated about 29,000 CGIs in the human genome and that about 60% 
are associated with human genes (Lander et al., 2001; Venter et al., 2001). A 
small proportion of these CGIs become methylated during development 
(Kierszenbaum, 2002; Robertson and Wolffe, 2000; Smale, 2003) whereas a 
significant portion are progressively methylated in certain tissues during aging 
(Issa, 2000).  
1.2 The DNA methylation machinery 
Cytosine methylation patterns in mammals are established by a complex 
interplay of modifying enzymes called DNMT. Five DNMTs are currently 
known: DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L. Of these, the 
first four have been proven to have activity (Hermann et al., 2003; Okano et al., 
1998a; Pradhan et al., 1999) whereas DNMT3L which lacks several conserved 
catalytic motif was predicted to have none (Aapola et al., 2000). For chemical 
modification of the target base to occur, the DNMT "flip" the target base out of 
the DNA double helix and into the active site of the enzyme (Cheng and Roberts, 
2001; Huang et al., 2003; Jeltsch, 2002). This phenomenon was observed for 
DNMTs and for DNA base excision repair enzymes and suggested to be a 
general mechanism for such enzymes to gain access to the target or errant 
nucleotide, depending on the function of the enzyme (Cheng and Blumenthal, 
2008; Cheng and Roberts, 2001). The DNMT enzyme may be divided into two 
domains; the small domain consists of the co-factor (S-adenosyl-L-methionine 
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(Adomet)) binding site and the catalytic site whereas the large domain mediates 
the recognition of the DNA sequence that is characteristic of the specific 
enzyme (Figure 1.2) (Cheng, 1995; Cheng and Blumenthal, 2008; Cheng and 
Roberts, 2001; Jeltsch, 2002).  
 
Figure 1.2. Schematic diagram of all the catalytically active DNMTs. Roman 
numerals refer to conserved motifs of DNMTs. 
1.2.1 DNMT1 
DNA cytosine-5 methyltransferase 1 (DNMT1) was the first mammalian 
enzyme to be isolated (Bestor et al., 1988). It is a large protein of 1616 amino 
acid (aa)(Figure 1.2) and functions as a maintenance methyltransferase (Bestor, 
2000; Jeltsch, 2002; Robertson, 2001; Robertson, 2002). The N-terminal of this 
enzyme is responsible for a variety of protein-protein interaction; including 
targeting to the replication foci in S-phase by binding to the proliferating cell 
nuclear antigen (PCNA) (Chuang et al., 1997; Iida et al., 2002), recruitment of 
histone deacetylases (HDACs) through its bromo-adjacent homology (BAH) 
domain (Callebaut et al., 1999) and also interacting with HDAC1, E2F1 and Rb 
tumor suppressor protein (Robertson et al., 2000).  
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 DNMT1 shows a significant preference (30 - 40 fold) for hemi-
methylated DNA (Fatemi et al., 2001; Jeltsch, 2006; Margot et al., 2000; 
Pradhan et al., 1999) and thus have been suggested to have a role in 
maintenance methylation in vivo. The role as a maintenance DNMT is further 
supported by the observations that DNMT1 localizes to replication foci in the S-
phase, and processively methylates DNA as the genome is being replicated 
(Jeltsch, 2006; Leonhardt et al., 1992). This methylation maintenance process is 
kept under close scrutiny by a stress response mechanism to ensure a smooth 
propagation of the cellular DNA methylation signal (Milutinovic et al., 2003; 
Robertson, 2001).  
 Despite its important roles in the maintenance of genomic stability via 
faithful copying of the DNA methylation signals, dysregulation of DNMT1 have 
been implicated in tumors. DNMT1 is over-expressed in various tumor types 
and this over-expression was suggested to lead to hypermethylation of various 
genes in these tumors and associated with an increase in cell growth and 
invasion (Cheng et al., 2011; Issa et al., 1993; Kautiainen and Jones, 1986; 
Nagai et al., 2003; Robertson et al., 1999; Wu et al., 2011).  
1.2.2 DNMT2 
DNMT2 belongs to a large family of proteins that is well conserved from the 
yeast Schizosaccharomyces pombe to man (Van, I et al., 1998; Yoder and Bestor, 
1998). This small DNMT (391 aa) resembles the prokaryotic enzymes in that it 
do not contain a large N-terminal regulatory domain (Figure 1.2). Though this 
protein contains the signature ten highly conserved motifs of DNMT, its 
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methyltransferase activity remained elusive for some time (Dong et al., 2001; 
Van, I et al., 1998) before five independent groups demonstrated the activity of 
this enzyme (Hermann et al., 2003; Kunert et al., 2003; Liu et al., 2003; Narsa et 
al., 2003; Tang et al., 2003).  
 Though DNMT2 have been proven to be able to methylate CpGs, it was 
found to methylate DNA substrates at about one out of 250 cytosine residues 
with little sequence specificity and in a non-processive manner (Hermann et al., 
2003). In addition, knock-out of this enzyme in embryonic stem cells failed to 
elicit a phenotypic response with normal DNA methylation pattern (Okano et al., 
1998b) and Dnmt2 knock-out mice are viable and fertile with minor defects 
(Hermann et al., 2003). These observations suggested that DNMT2 may have 
additional functions not related to DNA methylation. Indeed DNMT2 has now 
been experimentally confirmed to have a transfer RNA (tRNA) 
methyltransferase activity recently and was further suggested to be a highly 
specific RNA methyltransferase rather than a DNMT (Goll et al., 2006; Rai et 
al., 2007). The biological role of DNMT2 is still unclear and more detailed 
analyses of DNMT2 in mammals will be very important in the understanding of 
the function of this protein. 
1.2.3 DNMT3  
The DNMT3 family consist of two active de novo DNMTs, DNMT3A and 
DNMT3B, and one regulatory protein DNMT3L (Bestor, 2000). Both 
DNMT3A and DNMT3B were isolated from database searches using bacterial 
DNMT as bait (Okano et al., 1998a). These two enzymes are 912 and 853 aa in 
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length respectively and together they share about 36% homology and over 80% 
homology in the C-terminal catalytic domain alone (Jeltsch, 2002). True to its 
suggested function as de novo DNMTs, these enzymes were shown to methylate 
DNA without a significant preference for hemi-methylated DNA (Gowher and 
Jeltsch, 2002; Okano et al., 1998a). Both enzymes are shown to be essential for 
de novo methylation in embryonic stem (ES) cells, postimplantation embryos 
and also methylation of imprinted genes (Hata et al., 2002; Okano et al., 1999). 
DNMT3A and DNMT3B are important during development as demonstrated 
using knockout mice; mice with DNMT3A knocked out were normal at birth but 
became runted and died at 4 weeks; no mice were born for DNMT3B knockout 
embryos which show many developmental defects including growth and neural 
tube defects (Okano et al., 1999).   
 Mutations in human DNMT3B have been reported to cause a severe, 
hereditary disease, ICF (immunodeficiency, centromere instability and facial 
anomalies) syndrome (Lappalainen and Vihinen, 2002; Tao et al., 2002b). 
Hypomethylation of the DNA is observed in these patients at the classical 
satellite regions 2 and 3 of chromosomes 1, 9 and 16; suggesting that DNMT3B 
may have a specialised function for methylating these areas (Lappalainen and 
Vihinen, 2002; Tao et al., 2002b). DNMT3B like DNMT1, is also found up-
regulated in tumors and suggested to play a role in tumorigenesis (Nagai et al., 
2003; Robertson et al., 1999). Both DNMT1 and DNMT3B were significantly 
over-expressed than normal cells in hepatocellular carcinoma (Bakin and Curran, 
1999; Nagai et al., 2003; Robertson et al., 1999). DNMT3B was also found to 
contribute substantially to the oncogenic phenotype in a lung cancer model by 
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supporting colony growth and silencing of TSGs (Soejima et al., 2003) and thus 
suggested to be an attractive target in cancer therapy. 
 DNMT3L was also identified by database analysis (Aapola et al., 2000) 
and have similar amino acid sequences with DNMT3A and DNMT3B over the 
cysteine rich PHD/ATRX domain. However DNMT3L lack some of the critical 
motifs required for the catalysis of methyl transfer and hence is an inactive 
methyltransferase. DNMT3L was noted to be highly expressed in testis and 
mouse embryos and was shown to be involved in gametogenesis and the 
establishment of genomic imprints (Bourc'his et al., 2001; Bourc'his and Bestor, 
2004; Webster et al., 2005). Murine Dnmt3L together with Dnmt3a were shown 
to be required for the proper establishment of maternal imprints and appropriate 
expression of maternally imprinted genes (Hata et al., 2002). Dnmt3L also co-
localizes and co-immunoprecipitate with Dnmt3a and Dnmt3b and enhances de 
novo methylation as a result of this interaction (Chedin et al., 2002; Chen et al., 
2005; Gowher et al., 2005). It was speculated that the function of Dnmt3L in the 
context of genomic imprinting in zygote is to stimulate Dnmt3a activity at 
certain imprinted loci to achieve a high enough density so as to survive the 
impending demethylation phase; in order to ensure proper propagation of the 
imprints (Chedin et al., 2002; Chen et al., 2005; Gowher et al., 2005; Kareta et 
al., 2006; Suetake et al., 2004). 
1.3 Aberrant promoter hypermethylation of tumor suppressor gene 
DNA methylation has been shown to affect the transcription of key genes 
involved in the regulation of cell growth, differentiation, apoptosis, 
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transformation and metastasis (Baylin and Jones, 2011; Jaenisch and Bird, 2003; 
Jones and Baylin, 2002). One of the most significant finding about CGIs 
methylation is that cancer cells exhibit genomic hypomethylation with focal 
hypermethylation (Bird, 2002; Feinberg and Vogelstein, 1983; Flatau et al., 
1983; Jones and Baylin, 2002). The focal methylation of CGIs observed in 
cancer cells was observed to be a non-random process when it was found that 
hypermethylation of gene-associated CGIs caused gene silencing and those 
frequently silenced are tumor suppressor genes (TSGs) (Baylin and Herman, 
2000; Baylin and Jones, 2011; Greger et al., 1989; Jones and Laird, 1999).  
 
Figure 1.3. The revised Kundson's two-hit hypothesis. (Figure reproduced from 
Peter A. Jones and Peter W. Laird, Cancer epigenetics comes of age, Nature Genetics) (Jones 
and Laird, 1999). 
Other than the “classical” ways of inactivating TSGs via genetic 
mutation and loss of chromosomal materials (loss of heterozygosity (LOH) or 
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homozygous deletion), a third increasingly recognized way of inactivating TSG 
is via promoter DNA methylation (Figure 1.3) (Jones and Laird, 1999). Aberrant 
promoter DNA methylation of TSG-associated CGIs is a characteristic hallmark 
of tumor genomic DNA, and examples of methylation silenced TSGs include 
p16INK4a, MLH1, VHL, RAR-beta, SOCS1 and others (Jones and Baylin, 2007; 
Rodriguez-Paredes and Esteller, 2011). TSG promoter DNA methylation result 
in gene silencing and the subsequent loss of function invariably cause disruption 
to the normal cellular processes. Hence epigenetically mediated gene silencing 
is increasingly documented as one of the major contributing factors pushing 
normal cells towards neoplastic transformation.  
In addition to being a hallmark of cellular transformation, aberrant DNA 
methylation of TSG promoter regions could provide potential tumor markers for 
early detection (Schwarzenbach et al., 2011; Tong and Lo, 2006). Assays for 
DNA methylation hold several advantages over the usual genetic assays like 
point mutations. It is a stable tumor-associated marker as acquired DNA 
methylation is generally not lost due to the nature of the methyl bond; one of the 
strongest known molecular bonds in nature (Jeltsch, 2002). Additionally, DNA 
methylation often occurs at 5’-promoter CpG islands of genes versus point 
mutations, which can happen anywhere on the gene exons (Baylin and Jones, 
2011; Jones and Baylin, 2002; Jones and Baylin, 2007).  
Although epigenetic alterations present in a single tumor is by no means 
unique to that particular tumor type, certain TSG are more frequently 
methylated and down-regulated in certain tumors (Jones and Baylin, 2007; Loyo 
et al., 2011). For example, promoter DNA hypermethylation of the pi-class 
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glutathione S-transferase P1 (GSTP1), deleted in liver cancer 1 (DLC1) and 
adenomatous polyposis coli (APC) frequently occur in prostate cancer, liver and 
colorectal cancer respectively (Ellinger et al., 2008; Taback et al., 2006; Wong 
et al., 2003a). Thus DNA methylation targets represent a stable and specific 
tumor marker, and we propose that these markers could potentially serve as 
molecular biomarkers and provide vital information to clinicians for early 
detection and monitoring of treatment effect in cancer patients. 
1.4 NPC Epidemiology and Incidence 
Compared to other cancers, Nasopharyngeal Carcinoma (NPC) can be 
considered as one of the rarer tumor type globally. It ranks as the 24th most 
common cancer worldwide and 22nd within the developing economies and has 
an estimated 84,400 cases and 51,600 deaths worldwide in 2008, contributing 
around 0.7% of the global cancer burden (Jemal et al., 2011). However NPC is 
characterized by a striking geographical and ethnic distribution (Figure 1.4) 




Figure 1.4. Estimated number of NPC cases and its distribution worldwide 
sorted according to continent. Top and bottom panels show the data for males and 
females respectively. Sourece: GLOBOCAN 2008. 
 NPC is rare in non-endemic regions but endemic in Asia which account 
for about 80% of all the NPC incidences in 2008 (Figure 1.4), with the highest 
incidence rates in both sexes recorded in South-East Asia  (Jemal et al., 2011). 
Globally the top 3 countries with the highest national NPC incidence rates are 
Malaysia, Indonesia and Singapore where NPC commonly afflict the Chinese 
and Malay population and men have a 2 to 3-fold higher risk compared to 
women (Figure 1.5) (Jemal et al., 2011; Lo et al., 2004). While the overall 
incidence is relatively low in China as a whole, NPC incidences are very high in 
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the southern provinces of China like the Guangdong province and Hong Kong 
where incidences of 25- 30 cases per 100,000 persons per year constitute the 
highest incidences in the world (Figure 1.6) (Chang and Adami, 2006; Lo et al., 
2004; Razak et al., 2010; Tao and Chan, 2007).  
 
Figure 1.5. Top 20 countries in 2008 showing the highest age-standardized  




Figure 1.6. The geographical distribution of nasopharyngeal carcinoma in 
China. Map showing the distribution of NPC mortality rate in China in the 1970s. Darker blue 
color indicates regions where the NPC mortality rate is higher than the Chinese national average. 
(Figure reproduced from: Qian Tao and Anthony T.C. Chan, Nasopharyngeal carcinoma: 
molecular pathogenesis and therapeutic developments, Expert Reviews in Molecular Medicine) 
(Tao and Chan, 2007) 
1.5 Histopathology 
NPC is a distinctive type of head and neck carcinoma and develops from the 
epithelial lining of the nasopharynx (Figure 1.7) (Lo et al., 2004; Tao and Chan, 
2007). The World Health Organization (WHO) classified NPC into 3 
histological subtypes based on the degree of differentiation (Shanmugaratnam 
and Sobin, 1991): 
 WHO Type I : Keratinizing squamous cell carcinoma 
 WHO Type II : Non-keratinizing squamous cell carcinoma 
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 WHO Type III: Undifferentiated carcinoma 
The WHO Type III NPC is also referred to as "lymphoepithelioma" based on a 
typical morphology characterized by a prominent lymphoplasmacytic infiltrate 
(Chou et al., 2008; Lo et al., 2004; Tao and Chan, 2007).  
 
Figure 1.7. Illustration showing the cross-section anatomy of a human head 
and neck.  
 The different sub-types differ in their epidemiologic incidences (Lo et al., 
2004; Tao and Chan, 2007). Type III NPC accounts for about 95% of all NPC 
cases in endemic areas like Southern China while Type II and I NPC are rare, 
accounting for 3% and 2% respectively (Chang and Adami, 2006; Marks et al., 
1998; Tao and Chan, 2007; Tse et al., 2006; Wei and Sham, 2005). In contrast, 
Type I NPC is more common in non-endemic areas such as North America, 
accounting for 25% of the total NPC cases with Types II and III NPC 
accounting for another 12% and 63% respectively (Chang and Adami, 2006; Lo 
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et al., 2004; Marks et al., 1998; Tao and Chan, 2007). Other than histological 
features, almost all NPC from endemic areas are reported to harbor latent 
Epstein-Barr Virus (EBV) infection but absent in Type I NPC in non-endemic 
areas (Chou et al., 2008; Lo et al., 2004; Raab-Traub, 2002). These observations 
may imply that Type I NPC has a distinctive etiology from the other two 
histological sub-types and that alternative tumorigenesis processes other than 
EBV may be involved in the development of Type I NPC in non-endemic 
regions. 
1.6 Etiology of NPC 
NPC is a disease that strongly afflict the Southern Chinese and that suggest the 
involvement of both genetic and environmental factors in its development. 
Although our knowledge of the molecular basis of NPC pathogenesis is still 
poor, it has been suggested that like other carcinomas, NPC development 
follows a multi-step process similar to colorectal carcinoma as first proposed by 
Vogelstein and Fearon in 1990 (Fearon and Vogelstein, 1990; Lo et al., 2004; 
Tao and Chan, 2007). Epidemiological studies on NPC have identified three 
major etiological factors in its pathogenesis and these include genetic factors, 
environmental factors and EBV. 
1.6.1 Genetic Factors 
The observation that Southern Chinese are more prone to NPC strongly suggests 
that this population of Chinese may be genetically predisposed to NPC. This 
view is reinforced by the observation that the second-generation of Chinese 
migrants from endemic areas continue to have a high incidence of NPC (Chang 
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and Adami, 2006; Tao and Chan, 2007). Familial clustering of NPC which 
contribute approximately 10% of the total NPC cases has also been reported 
widely thus lending further support to the genetic basis of NPC (Ho, 1972; 
JUNG, 1965; Loh et al., 2006; Tao and Chan, 2007; Zhang and Zhang, 1999).  
 The Human Leukocyte Antigen (HLA) association with NPC was first 
reported by Simons et al. in a Singaporean Chinese NPC cohort (Simons et al., 
1975). HLA genes encode for immune proteins required for the presentation of 
foreign antigens to the immune system and are essential for adaptive immunity. 
As almost all NPC tumors contain EBV, it was hypothesized that HLA alleles 
which present EBV antigens in a less antigenic fashion are associated with an 
increased risk of NPC (Hildesheim et al., 2002). Other studies have also shown 
HLA associations with virus-induced cancers such as cervical and liver cancers 
as well (Apple et al., 1994; Donaldson et al., 2001; Fanning et al., 2001; 
Hildesheim et al., 1998; Krul et al., 1999; Wang et al., 2002; Wank and 
Thomssen, 1991). Various groups have confirmed the HLA association with 
NPC in different ethnic groups and geographical settings and that the individual 
HLA factors implicated in the disease may vary due to population-dependent 
HLA distributions. Studies carried out over the years in endemic regions for 
NPC reported that HLA class I alleles such as HLA-A2, -B14, -B46, -B58 and -
B61 may predispose the carrier to NPC whereas HLA-A11, -A31, -B13, -B27, 
B39 and B55 may have a protective effect (Chan et al., 1983; Hildesheim et al., 
2002; Jing et al., 1977; Li et al., 2007; Lu et al., 2003; Pimtanothai et al., 2002; 
Simons et al., 1976).  
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 A recent comprehensive case-control study for HLA association of a 
NPC population in the Guangxi Province of Southern China found that while 
independent HLA alleles is associated with NPC protection, most NPC 
susceptibility is strictly associated with HLA haplotypes (Tang et al., 2010). 
Carriers of A*0206, B*3802 alleles and the high-risk HLA-A/B allele 
combinations A*0207-B*4601 and A*3303-B*5801 haplotypes are reported to 
show higher risk for NPC. In contrast, A*1101, B*27, and B*55 alleles was 
reported to associate with low risk for NPC. The A*0206 allele that is common 
in South and Southeast Asia was also reported for the first time to be associated 
with a high risk for NPC. The authors of this study attributed the high frequency 
of NPC to the high prevalence of NPC-susceptible HLA factors in Guangxi 
province (Tang et al., 2010).  
Results from a recent Genome-Wide Association Study (GWAS) to 
identify genetic susceptibility loci for NPC revealed the strong association of 
HLA-A*1101 with a reduced risk for NPC and additionally suggest multiple 
independent associations within HLA (Bei et al., 2010). The authors also 
analyzed data from another GWAS study (Tse et al., 2009) and suggested that 
HLA loci exert a stronger genetic effect than non-HLA loci in NPC. In addition,  
the strong association of HLA in non-Hodgkin lymphoma (another EBV 
associated malignancy) but not in other cancers was noted (Bei et al., 2010).  
In addition to the HLA genes, recent GWAS analyses further identified 
multiple candidate NPC susceptibility loci on 6p21.3 (Li et al., 2011; Tse et al., 
2009), 13q12 (Bei et al., 2010), 3q26 (Bei et al., 2010) and 9p21 (Bei et al., 
2010). However due to the large number of genes within the chromosomal 
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regions involved, it is difficult to pin-point the relevant NPC gene/s involved in 
the pathogenesis of NPC. It must be noted that genetic factors alone cannot fully 
explain the case of NPC as environmental exposures is likely to play a major 
role as well. Indeed, a segregation analysis to explain the inheritance of familial 
NPC in Southern China suggest that NPC arise due to multiple genetic and 
environmental factors rather than a single major susceptibility gene mutation 
(Jia et al., 2005). 
1.6.2 Environmental Factors 
NPC has a strong association with Cantonese and one of the strongest cultural 
habits linked to this dialect group is the consumption of Cantonese-styled salt-
preserved fish. Salt-preserved fish and other preserved food items frequently 
contain volatile nitrosamines as a by-product of the salting process and these 
chemicals are mutagenic in nature (Mirvish, 1995).  
 In population studies of Chinese in NPC endemic areas, weekly 
consumption of this traditional food item was found to increase the relative risk 
of NPC from 1.4 to 3.2 for those with no or occasional consumption, to 1.8 to 
7.5 for those with daily consumption (Armstrong et al., 1998; Henderson and 
Louie, 1978; Yu et al., 1989a; Yu et al., 1986; Yuan et al., 2000; Zou et al., 
2000). A murine model in which a diet of salt-preserved fish increased the 
development of nasal and nasopharyngeal tumors in a dose dependent manner 
lent further support to this hypothesis (Ho, 1972; Huang et al., 1978; Lancet., 
1989; Yu et al., 1989b; Yu and Yuan, 2002; Zheng et al., 1994). Ingestion of 
other preserved food and the use of Chinese herbs have also been linked with 
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NPC pathogenesis (Gallicchio et al., 2006). Indeed, a two-fold increase in NPC 
risk is associated with preserved vegetable intake whereas a 36% decrease is 
associated with fresh vegetable intake (Gallicchio et al., 2006).   
1.6.3 Epstein-Barr Virus 
Other than genetic and environmental factors, EBV infection is consistently 
associated with NPC. EBV is a ubiquitous human B-lymphotropic herpesvirus 
that infects and persists latently in more than 90% of the world's population 
(Rickinson and Kieff, 2001). Primary EBV infection is normally subclinical but 
the virus is consistently associated with development of several malignancies 
including NPC (IARC, 1997). Transmission of this virus is mainly through 
saliva and occurs earlier in life in developing countries (Mueller et al., 1996). A 
study in Hong Kong found that about 80% of children have been infected with 
EBV by age 6 with nearly 100% sero-conversion rates by age 10 (Kangro et al., 
1994). The natural targets for EBV infection are B-lymphocytes where it 
persists in latent infection in resting B-cells. The mechanisms for EBV entry 
into epithelial cells is still unclear but other than B-cells and nasopharyngeal 
epithelial cells, EBV have also been found in oropharyngeal and gastric 
epithelial cells as well (Lo et al., 2004; Takada, 2000; Yanai et al., 1997). 
 The association of EBV within NPC was first suggested in the 1960s 
when NPC patients were found to express antibodies against EBV lytic cycle 
antigens (Old et al., 1966). This association was later confirmed when NPC 
patients was shown to express higher anti-EBV titers compared to healthy 
controls and when EBV DNA and EBV nuclear antigen (EBNA) were 
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consistently detected  in NPC tumors (Henle et al., 1970; Raab-Traub, 2002; zur 
Hausen et al., 1970). Southern blot analyses in NPC tumor cell DNA 
demonstrated that the EBV genome was clonal and thus suggested that NPC 
originated from a single progenitor cell infected with EBV before clonal 
expansion (Gulley et al., 1995; Jiang and Yao, 1996; Pathmanathan et al., 1995; 
Raab-Traub and Flynn, 1986). In NPC tumors, EBV is present in every tumor 
cell in the form of an episome and is generally absent in the surrounding normal 
cells (Nicholls et al., 1997; Sam et al., 1993; Tao et al., 1995). EBV was also 
suggested to play a role in the early stages of tumor development after clonal 
EBV was detected in severe dysplasia or carcinoma in situ (CIS) of the 
nasopharynx (Pathmanathan et al., 1995; Yeung et al., 1993). In light of the 
evidences presented above, it was suggested that EBV plays a significant role in 
NPC development; possibly pushing the normal cell towards malignancy in the 
earliest NPC lesion (severe dysplasia or CIS) via the expression of several 
oncoproteins like the latent membrane protein 1 (LMP1) (Tao et al., 2006; Tao 
and Chan, 2007). 
 EBV exists in three different latency forms in normal and tumor cells 
based on specific gene expression signatures. Latency type I as observed in 
some normal peripheral blood mononuclear cells (PBMCs), Burkitt lymphoma 
(BL) and gastric carcinoma (GC) is characterized by a tightly restricted EBV 
gene expression signature with only EBV nuclear antigen-1 (EBNA1)(driven off 
from the Q promoter (Qp)) , EBV-encoded RNAs (EBERs), latent membrane 
protein-2A (LMP2A) and BamHI-A rightward transcripts (BARTs) transcribed 
(Rowe et al., 1987; Sbih-Lammali et al., 1996; Tao et al., 2006; Young and 
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Rickinson, 2004). Latency type II is characterized by the expression of EBNA1 
(Qp driven), EBERs, BARTs, LMP1 and LMP2. The BamHI-A reading frame-1 
(BARF1) gene is also expressed in all type II latency EBV positive tumors 
except HL. This latency program is present in the majority of EBV-positive 
tumors like NPC, Hodgkin lymphoma (HL), nasal natural killer (NK)/T-cell 
lymphoma and several T-cell lymphomas (Liebowitz and Kieff, 1993; Shah and 
Young, 2009; Tao et al., 2006; Young and Rickinson, 2004). The final pattern of 
gene expression (latency type III) mainly occurs in immunocompromised 
individuals suffering from Acquired immuno-deficiency syndrome (AIDS)-
related proliferative disorders; post-transplant lymphoproliferative disorders 
(PTLD) and also in EBV-immortalized lymphoblastoid cell lines (LCLs). This 
latency type III involves the expression of all six EBNAs (EBNA1, 2, 3A, 3B, 
3C, and LP) from the EBV C promoter (Cp) and/or W promoter (Wp), EBERs 
(EBER1 and 2), LMPs (LMP1, 2A and 2B) and BARTs (Liebowitz and Kieff, 
1993; Niedobitek et al., 1997; Tao et al., 2006; Young and Rickinson, 2004). A 
latency type 0 where EBV infected B-cells express no detectable latent mRNA 
or protein is known but its existence is still controversial (Shah and Young, 
2009; Young and Rickinson, 2004). 
 Other than these EBV encoded proteins, EBV is the first virus known to 
have genes coding for at least 17 microRNAs (miRNA) and these have been 
detected in NPC and gastric carcinoma (Cai et al., 2006; Kim et al., 2007; 
Pfeffer et al., 2004; Zhu et al., 2009). A recent study reported that an EBV 
encoded miRNA, miR-BART5, regulates an important mediator of cellular 
apoptosis, the p53 up-regulated modulator of apoptosis (PUMA) protein. miR-
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BART5 is highly expressed in NPC and EBV positive gastric carcinoma cells 
and was shown to modulate PUMA expression in EBV positive cells rendering 
the cells less sensitive to proapoptotic agents and which can be reversed via 
depletion of miR-BART5 or forced expression of PUMA (Choy et al., 2008). 
Another study showed that the EBV encoded miRNA BHRF1-3 controls the 
virus latency stage by regulating the levels of its candidate cellular target, the C-
X-C motif ligand 11/IFN-inducible T-cell attracting chemokine (CXCL-11/I-
TAC) and that targeted suppression of CXCL-11/I-TAC by this virus encoded 
miRNA may serve as an immunomodulatory mechanism in these tumors (Xia et 
al., 2008). Other than silencing cellular genes, EBV encoded miRNA are also 
involved in auto-regulatory mechanisms. miR-BART6 was found to suppress 
EBNA2, required for transition from the less immunologically responsive 
latency type I and II to the more immuno-reactive latency type III. EBNA2 
suppression also down-regulated the Zta and Rta viral proteins essential for lytic 
replication thus revealing the auto-regulatory function of miR-BART6 in EBV 
infection and latency (Iizasa et al., 2010). Although the functions of many other 
EBV encoded miRNAs remain largely unknown, they are nevertheless 
postulated to play important roles in the viral life cycle. 
 In NPC, EBV adopts a latency type II program which sees the expression 
of EBNA1 and EBERs in all EBV-positive NPC cases (Tao et al., 2006; Tao and 
Chan, 2007). Expression of the LMP1 oncoprotein however is more variable 
with immunohistochemical and western blot analyses showing the presence of 
LMP1 protein in 20-65% of cases, whereas more sensitive methods using nested 
Reverse Transcription -Polymerase Chain Reaction (RT-PCR) reported 
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expression in more than 90% of cases (Brooks et al., 1992). In C666-1 which is 
the only EBV-positive NPC cell line available, LMP1 is barely expressed, likely 
due to the methylated promoter DNA (Cheung et al., 1999). Interestingly, LMP1 
expression is associated with a better prognosis in NPC patients, presumably 
due to the ability of LMP1 to elicit a strong immune response (Fahraeus et al., 
1988; Young et al., 1988). LMP2A on the other hand have been confirmed by 
various studies to be expressed in a high proportion of NPC cases (Brooks et al., 
1992; Chen et al., 1995; Heussinger et al., 2004). Several studies also found the 
expression of the transforming  EBV oncogene BARF1 and BARTs miRNA in 
almost all NPC tumors, thus suggesting an oncogenic role for these molecules 
(Chen et al., 1992; Decaussin et al., 2000; Sheng et al., 2003). 
1.7 Molecular alterations and pathogenesis 
Genetic, environmental and the EBV factors are likely to work together in 
concert and lead to the accumulation of a number of genetic and epigenetic 
changes that alter the functions of genes that are critical for proliferation, 
apoptosis and differentiation and ultimately the development of NPC. Studies on 
pre-malignant and NPC tumors has identified specific genetic changes and has 
led to the proposal of a multi-step model for NPC pathogenesis (Chan et al., 
2000; Chan et al., 2002; Lo et al., 2004; Lo and Huang, 2002; Shah and Young, 
2009; Tao and Chan, 2007). Comprehensive genome-wide studies in NPC have 
identified multiple consistent genetic losses on chromosome 3p, 9p, 9q, 11q, 14q 
and 16q while recurrent chromosomal gains were reported on chromosome 1q, 
3q, 7q, 8q, 11q, 12p, 12q, 19p and 19q (Chan et al., 2004; Hui et al., 2002; Or et 
al., 2010; Wong et al., 2003b). 
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 Specific amplifications in NPC frequently led to the over-expression of 
several known or putative oncogenes like BCL2, CCND1, EGFR, LTBR, 
GPR160, SKIL, etc.  in NPC pathogenesis resulting in multiple abnormalities 
associated with apoptosis and growth signals (Hui et al., 2002; Hui et al., 2005; 
Or et al., 2010; Sheu et al., 2009; Sheu et al., 1997). Consistent B-cell lymphoma 
2 (BCL2) amplification and up-regulation of BCL2 activity was found in early 
precancerous lesions and suggests that dysregulation of the apoptotic pathways 
is an early event in NPC pathogenesis (Sheu et al., 1997). Lymphotoxin beta 
receptor (LTBR) is amplified in NPC tumors bearing the 12p13.3 amplification 
and belongs to the Tumor Necrosis Factor (TNF) family of receptors which can 
modulate Nuclear factor kappa-B(NFκB) signaling pathways. Over expression 
of LTBR up-regulated NFκB activity resulting in cell proliferation and this 
phenomenon can be reversed by suppression of LTBR by siRNA with 
concomitant growth inhibition observed in vivo (Or et al., 2010). 
 Loss of chromosomal region 3p and 9p21 are the most common genetic 
changes detected and occur early in the progression of NPC with 3p and 9p21 
deleted in up to 95% and 85% of invasive tumors assayed respectively (Chan et 
al., 2004; Shah and Young, 2009). The southern Chinese population in Hong 
Kong was found to have a higher frequency of 3p/9p losses in the normal 
nasopharyngeal epithelium when compared to lower risk Chinese population. In 
addition, this elevated loss of 3p and 9p in normal nasopharynx was found 
before EBV infection and was suggested to predispose nasopharyngeal cells to 
latent EBV infection, a crucial event in the multi-step progression towards NPC 
(Chan et al., 2000; Chan et al., 2002; Chan et al., 2004; Shah and Young, 2009). 
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Candidate genes on 9p21 including p16, p15 and p14ARF and RASSF1A and BLU 
on 3p21.3 were found to be silenced/defective due to deletion, promoter 
hypermethylation or mutation and their tumor suppressive properties have been 
demonstrated in multiple studies (Agathanggelou et al., 2003; Chow et al., 2004; 
Gulley et al., 1998; Lo et al., 1995; Lo et al., 1996; Qiu et al., 2004; Sun, 2005; 
Zhou et al., 2005). 
 The frequent promoter DNA hypermethylation of tumor suppressor 
genes (TSGs) is an important characteristic of NPC. Other than the common 
TSGs like RASSF1A, p16 and CDH1, widespread hypermethylation of the NPC 
genome is observed and hypothesized to disrupt a significant number of 
pathways and hence suggest a "methylator" phenotype for NPC (Lo et al., 1996; 
Wong et al., 2006; Wong et al., 2003c). EBV infection is also proposed to induce 
the epigenetic alteration of cellular genes and suggested as an important 
mechanism for driving NPC pathogenesis (Lo and Huang, 2002). Some of the 
cellular signaling pathways disrupted include the endothelin-1 pathway 
(EDNRB), loss of cell adhesion (CDH1, PCDH10), inactivation of the retinoid 
signaling pathway (RARB2), chromatin remodeling (PRDM2/RIZ1) and many 
others (Chang et al., 2003; Lo et al., 2002; Tao and Chan, 2007; Wong et al., 
2003c; Ying et al., 2006). Extensive DNA methylation studies done by several 
groups further increased our knowledge of putative TSGs involved in NPC 
pathogenesis and silenced via DNA methylation, including GADD45G, TSLC1, 
DLC1, DLEC1, ZNF382, and UCHL1 and many more new genes are 
increasingly reported (Cheng et al., 2010; Hui et al., 2003; Kwong et al., 2007; 
Li et al., 2010; Low et al., 2011; Seng et al., 2007; Ying et al., 2005). It is 
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hypothesized that many candidate TSGs silenced via promoter DNA 
methylation still remain largely undiscovered. The elucidation of these novel 
TSG candidates will surely increase our knowledge of the intricate pathways 
involved in the regulation of the cancer genome and in addition, could serve as 
important epigenetic biomarkers for molecular diagnostic and prognostic 
purposes in patients. Hence this project aim to discover and characterize novel 
tumor suppressor gene candidates silenced via promoter DNA methylation in 
NPC and other tumors. 
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Chapter 2: A novel isoform of the 8p22 tumor suppressor gene 




Carcinogenesis involves multiple genetic/epigenetic events including the 
activation of oncogenes and inactivation of tumor suppressor genes (TSGs) 
(Fearon and Vogelstein, 1990; Knudson, 2001). In addition to genetic mutations, 
a growing body of evidence has shown that TSG inactivation occurs frequently 
through promoter CpG methylation (Herman and Baylin, 2003; Jones and Laird, 
1999), resulting in TSG silencing and subsequent loss of function, thereby 
contributing to neoplastic transformation (Jones and Baylin, 2007). Aberrant 
CpG methylation of TSG-associated CpG islands is a characteristic hallmark of 
tumor genomic DNA, and examples of methylation silenced TSGs include p16, 
MLH1, VHL, RAR-beta, SOCS1, PCDH10, RASAL and so on (Herman and 
Baylin, 2003; Jones and Baylin, 2007). 
 Deleted in liver cancer 1 (DLC1) gene (also known as ARHGAP7, 
STARD12, HP and p122-RhoGAP) was isolated by representational difference 
analysis (Yuan et al., 1998) from a sample of human hepatocellular carcinoma 
(HCC), and proposed as a candidate TSG because of its frequent deletion in 
hepatocellular carcinoma tumors and cell lines. Located at 8p22, a site of 
recurrent deletion in breast, lung and prostate cancers (Yuan et al., 1998), DLC1 
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encodes a protein of 1091-aa (amino acid) with extensive homology (86%) to 
the rat p122-RhoGAP, a GTPase-activating protein (GAP) specific for RhoA 
and Cdc42 that are involved in the regulation of cellular cytoskeleton 
organization and other functions (Bernards, 2003; Durkin et al., 2007b; Homma 
and Emori, 1995; Sekimata et al., 1999; Wong et al., 2003a; Yuan et al., 1998). 
Subsequent studies identified DLC1 as an epigenetically silenced gene with 
tumor suppressive and metastatic inhibitory functions in breast, liver, colon, 
lung, stomach and brain cancers (Kim et al., 2003; Pang et al., 2005; Yuan et al., 
2003; Yuan et al., 2004; Zhou et al., 2004). Recently, using suppression 
subtractive hybridization, our group identified DLC1 as an epigenetically 
silenced gene in nasopharyngeal (NPC), esophageal and cervical carcinomas 
(Seng et al., 2007), thus further supporting the view that DLC1 is a bona fide 
TSG. 
 DLC1 is a member of the human RhoGAP family. RhoGAP proteins 
share a conserved 150–200-aa GAP domain that contains the catalytic activity to 
convert the active GTP-bound Rho proteins to the inactive GDP-bound state 
(Bernards, 2003; Durkin et al., 2007b; Moon and Zheng, 2003; Tcherkezian and 
Lamarche-Vane, 2007). Loss of RhoGAP activity leads to aberrant activation of 
GTP-bound Rho proteins, which are involved in the regulation of the cell cycle, 
adhesion, morphogenesis, polarity and migration; and dysregulation of GTP-
bound Rho proteins have been implicated in tumorigenesis (Martin, 2003; Moon 
and Zheng, 2003). Members of the DLC family include DLC1, DLC2, and 
DLC3, and their domain structures share an N-terminal sterile α motif domain, a 
serine-rich domain, a RhoGAP domain and a C-terminal steroidogenic acute 
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regulatory protein-related lipid transfer domain (Ching et al., 2003; Durkin et al., 
2007a; Ponting and Aravind, 1999; Yuan et al., 1998). Recently, Yuan et al. 
(Yuan et al., 2007) showed that DLC1 harbors a functional bipartite nuclear 
localization signal which works together with the RhoGAP and serine-rich 
domain to mediate DLC1 protein nuclear transfer and subsequent apoptosis in 
non-small-cell lung carcinoma cells . In addition, DLC1 knockdown in the 
background of c-myc over-expression promotes the formation of liver tumors in 
a murine model (Xue et al., 2008). Taken together, these data suggest that DLC1 
function both as a cytoplasmic and nuclear tumor suppressor, and highlight the 
importance of DLC1 in cancer development. 
 During our study of DLC1, we discovered a new isoform through 5′-
rapid amplification of complementary DNA (cDNA) ends (5′-RACE). Here, we 
report the characterization of this novel isoform (designated DLC1-isoform 4 
(DLC1-i4)), its mRNA expression and epigenetic alterations in multiple 
carcinomas. We also describe the response of the DLC1-i4 promoter to p53 and 
the expression of the two other DLC1 isoforms (-i1 and -i3) in human cells. 
Lastly, we demonstrate that DLC1-i4 and -i1 suppress tumor cell colony 
formation. 
2.2 Materials and Methods 
2.2.1 Cell lines, tumor and normal tissue samples 
Tumor cell lines used in this study are described elsewhere  (Ying et al., 2005) 
include NPC, esophageal, gastric, breast, colorectal, cervical, lung, 
hepatocellular, renal, prostate, ovarian carcinomas, Burkitt lymphoma, nasal 
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NK/T-cell lymphoma and Hodgkin lymphomas (Supplementary Figures). 
Epithelial cell lines (HMEC and HMEpC) and immortalized epithelial cell lines 
(NP69, RHEK1, HEK293, NE1 and NE3) were used as normal controls. Cell 
lines were routinely maintained in RPMI or DMEM, or Keratinocyte SFM 
Medium (for NP69 only) (Lo et al., 2006; Tsao et al., 2002). Total RNA and 
DNA were extracted from cell pellets using TRI Reagent (Molecular Research 
Centre Inc., Cincinnati, OH, USA)(Tao et al., 2002a). Normal PBMCs from 
healthy individuals were collected as previously described (Cheung et al., 1993). 
Human normal adult and fetal tissue RNA samples were purchased 
commercially (Seng et al., 2007; Ying et al., 2006). RNA from matched human 
breast primary tumor and normal tissue pair was purchased from Biochain 
(Hayward, CA, USA). DNA extracted from primary tumors are described 
elsewhere (Cui et al., 2008; Qiu et al., 2004; Seng et al., 2007; Tao et al., 1998; 
Tao et al., 1999a; Ying et al., 2005; Ying et al., 2006). 
2.2.2 5′ RLM-RACE 
5′-RLM-RACE was carried out with RNA from NP69 cell line and liver RNA 
(BD Clontech, Palo Alto, CA, USA), using the FirstChoice RLM-RACE kit 
(Ambion Inc., Austin, TX, USA) according to the manufacturer's protocol. 
Reverse transcription was carried out with random hexamers and nested PCR 
used to amplify the 5′ end of DLC1 transcripts using kit provided sense primers 
and antisense primers specific to both DLC1-i1 and -i2 (Primer sequences 
available in Table 2.1). Nested PCR amplification was carried out in a 25 μl 
volume consisting of 1 μl of cDNA, 0.6 U of AmpliTaq Gold (PE Biosystems, 
Foster City, CA, USA), 0.6 μM of each primer, and 2 mM MgCl2. The 
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amplification cycle involve an initial ‘hot start’ at 95 °C for 10 min, followed by 
35 cycles of amplifications (94 °C, 30 s; 55 °C, 30 s; 72 °C, 2 min) with a final 
extension step of 72 °C for 10 min. Nested PCR reaction was diluted 10 × with 
sterile water and 1 μl of the diluted reaction was used for subsequent nested 
PCR with the same conditions. PCR products were analyzed on 1.8% agarose 
gels. Two bands of 205 bp and 199 bp from Liver and NP69, respectively, were 
excised, purified and sequenced with the ABI PRISM BigDye v1.1 Kit (PE 
Biosystems) with the inner primer E10R. 
2.2.3 Bioinformatics analysis 
Sequences obtained were analyzed using BLASTN (Altschul et al., 1990) 
program (www.ncbi.nlm.nih.gov/blast). Gene structure and orthologs were 
obtained from GenBank (www.ncbi.nlm.nih.gov/entrez/query.fcgi? 
CMD=search&DB=gene) and Ensembl databases (http://www.ensembl.org) 
(Flicek et al., 2010; Maglott et al., 2007). Alignment of amino acid (aa) 
sequences and phylogenetic tree generation were carried out using the 
ClustalW2 program (http://www.ebi.ac.uk/Tools/clustalw2/index.html)(Larkin 
et al., 2007) and shaded using BioEdit 7.0.1 
(www.mbio.ncsu.edu/BioEdit/bioedit.html)(Hall, 1999). Potential TF-binding 
sites on DLC1-i4 promoter were predicted using TFSEARCH 
(www.cbrc.jp/research/db/TFSEARCH.html)(Akiyama, 1995; Heinemeyer et al., 
1998), MotifSearch (www.motif.genome.jp/)(Heinemeyer et al., 1999) and 
MatInspector (www.genomatix.de)(Cartharius et al., 2005). CpG island was 
predicted with CpG Island Searcher (www.uscnorris.com 
/cpgislands2/cpg.aspx)(Takai and Jones, 2002; Takai and Jones, 2003) using 
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default settings. N-terminal signal peptide analysis were done using iPSORT 
(http://hc.ims.u-tokyo.ac.jp/iPSORT/)(Bannai et al., 2002), MitoProt II 
(http://ihg2.helmholtz-muenchen.de/ihg/mitoprot.html)(Claros and Vincens, 
1996), Predotar (http://urgi.versailles.inra.fr/predotar/predotar.html) (Small et al., 
2004), Mitopred (http://bioapps.rit.albany.edu.libproxy1.nus.edu.sg/ 
MITOPRED/)(Guda et al., 2004a; Guda et al., 2004b) and TargetP 1.1 
(http://www.cbs.dtu.dk/services/TargetP/)(Emanuelsson et al., 2007). 
2.2.4 Semi-quantitative RT–PCR 
RT–PCR was done as previously described (Tao et al., 1998; Tao et al., 2002b), 
with primers in Table 2.1, together with house-keeping gene GAPDH as a 
control. RT–PCR was performed for 35 cycles for all genes except GAPDH (25 
cycles), using the GeneAmp RNA PCR system (Applied Biosystems). 
2.2.5 Gene reporter assays 
From normal placenta DNA (Sigma-Aldrich Corporation, St Louis, MO, USA), 
three regions of the putative DLC1-i4 and -i1 promoter were PCR amplified 
using a high-fidelity DNA polymerase, Phusion (Finnzymes, Espoo, Finland) 
and ligated to the promoter-less pGL2-Enhancer vector (Promega, Madison, WI, 
USA) to create pGL2-DLC1i4-PF1/R(−1840/+140), pGL2-DLC1i4-
PF2/R(−960/+140), pGL2-DLC1i4-PF3/R(−480/+140); pGL2-DLC1i1-
F1/R(−1272/+286), pGL2-DLC1i1-F2/R(−656/+286) and pGL2-DLC1i1-
F3/R(−376/+286). The p21 promoter plasmid (pGL2–p21P) was a kind gift 
from Drs Satya Narayan and Bert Vogelstein (University of Florida, Gainesville, 
FL, USA; Johns Hopkins, Baltimore, MD, USA). Plasmids used for transfection 
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were prepared and purified using the Endofree Plasmid Maxi Kit from Qiagen 
(Qiagen GmbH, Germany). Promoter activities were tested by co-transfection of 
cell lines (HEK293, CNE2 and HK1) in 12-well plates with 2 μg of promoter 
construct and 100 ng of Renilla Luciferase plasmid pRL-SV40 as an internal 
control using Fugene 6 (Roche Diagnostics, Mannheim, Germany). Transfected 
cells were grown for 48 h before luciferase assay using the Dual Luciferase 
Reporter Assay System (Promega). Three independent assays were conducted 
and the mean±s.d. values were calculated. 
 To assess the effect of p53 on DLC1-i4 promoter activity, concentrations 
of the p53 expression vector ranging from 1 to 500 ng (pcDNA3.1(+)TP53) or 
two mutant p53 expression constructs (G245C and R248W) (gifts from Bert 
Vogelstein) were cotransfected with 2 μg of pGL2-DLC1i4-PF1/R(−1840/+140) 
and 100 ng pRL-SV40 into respective cells lines. For comparative purposes, the 
p21 promoter construct pGL2–p21P was used as a positive control for p53-
dependent transcriptional activation. For UV treatment, cells after transfection 
are allowed to grow for 48 h and the growth medium removed before irradiation 
with 10 J/m2 UV in a Stratalinker UV Crosslinker 1800 (Stratagene, La Jolla, 
CA, USA). After UV irradiation, growth media were replaced and incubated for 
a further 2–6 h before luciferase assay. 
2.2.6 Construction of expression plasmids 
The full-length cDNA of DLC1-i4 and -i1 with a Hemagglutinin tag at its N-
terminus and its ATG ‘start’ codon within a Kozak consensus sequence (Kozak, 
1986; Kozak, 1987), and the common ‘stop’ codon present in exon 21 (Figure 
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2.1a) was PCR cloned from human liver-tissue RNA (BD Clontech) using a 
high-fidelity DNA polymerase, Phusion . The cDNA was then restriction 
enzyme digested, cloned into the expression vector pcDNA3.1(+) (Invitrogen, 
Carlsbad, CA, USA) and sequenced. pcDNA3.1(+)TP53 was constructed by 
subcloning the full-length wild-type TP53 from plasmid pC53-SN (gift from Dr 
Bert Vogelstein) into pcDNA3.1(+). The two mutant p53 expression constructs 
(G245C & R248W) were also gifts from Dr Bert Vogelstein. 
2.2.7 Bisulfite treatment and promoter methylation analysis 
Bisulfite modification of DNA and the subsequent MSP and BGS analyses were 
previously described (Tao et al., 1999b; Tao et al., 2002b). MSP and BGS 
primer sets are listed in Table 2.1. All primer sets were previously tested for not 
amplifying any unbisulfited DNA. For BGS, the PCR products were TA-cloned 
into the pCR2.1-TOPO vector (Invitrogen) and 5–12 colonies were randomly 
chosen and sequenced. All PCR reactions were carried out using the AmpliTaq-
Gold DNA polymerase (Applied Biosystems). 
2.2.8 Aza and TSA treatment 
Freshly seeded cells (C666-1 and HK1) at a concentration of 1 × 105 cells per ml 
in T-75 flasks were grown overnight with fresh medium containing Aza (Sigma, 
St. Louis, MO) at a final concentration of 50 μM (Qiu et al., 2004; Ying et al., 
2005). Cells were treated continuously for 72 or 144 h, with the Aza-containing 
medium changed every 24 h before being harvested for DNA and RNA 
extraction. For trichostatin A (TSA)(Sigma, St. Louis, MO) treatment, cells 
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(HCT116, EC109 and HK1) were treated as above for 72 h using 10 μM of Aza 
and subsequently for another 24 h with 100 ng/ml TSA. 
2.2.9 Colony formation assays 
HCT116, HK1 and EC109 cells (3 × 105 cells per ml) were plated in a 12-well 
plate and allowed to grow for 24 h before being transfected with 2 μg of 
expression plasmids or empty vector using Fugene 6 (Roche Diagnostics) 
according to the manufacturer's protocol. At 48 h post-transfection, transfected 
cells were trypsinized and diluted into 6-well plates with G-418 (500 μg/ml) 
selection for 2–3 weeks. Surviving colonies (with >50 cells per colony) were 
counted and analyzed after staining with Gentian Violet. The experiment was 
repeated thrice independently. 
2.2.10 Accession number 
The sequences of the RLM-RACE products of DLC1 from liver and NP69 have 










2.3.1 5′-RNA ligase-mediated rapid amplification of cDNA ends (5′ RLM-
RACE) identifies a novel isoform of DLC1 (DLC1-i4) and expression 
profiles of all four isoforms in normal tissues 
To identify novel isoform(s) of DLC1, 5′-RLM-RACE was performed on NP69 
and liver total RNA using antisense primers targeting the DLC1 common exons 
9 and 12 (Table 2.1 and Figure 2.1a). Two PCR bands of 205 bp and 199 bp 
were obtained and sequenced. Sequence analysis identified two transcriptional 
start sites only 6 bp apart and overlapped with a previously deposited partial 
cDNA sequence (AK025544) in NCBI database (Figure 2.1b). Subsequent 
BLAST searches identified 15 expressed sequence tags (Genbank accession: 
DA853751, DA409883, DA403097, DA401187, DA231722, DA328255, 
DA334650, BP287999, BP285601, CN388450, BX474714, BX474696, 
BP238467, CN388449 and BP287477) with their transcriptional start sites close 




Figure 2.1: mRNA expression, exon and protein structure of the various 







human DLC1 gene (not drawn to scale). The DLC1 gene contains internal promoters and 
expresses multiple isoforms. Boxes represent exons and are numbered to correspond to coding 
exons of the various DLC1 isoforms with the 5′-most exon denoted as exon 1 (exon 1 of 
isoforms 1 and 3). Closed boxes indicate exons common in all DLC1 isoforms except isoform 3. 
Bent arrows indicate the transcriptional start sites of the various DLC1 isoforms. Black, dotted, 
gray and dashed lines indicate the splicing structure for isoform 1, 2, 3 and 4, respectively. 
Primer locations are shown by short black arrows. (b) The CpG island promoter of DLC1-i4. 
Sequences of the DLC1-i4 promoter, first exon and the locations of the BGS and MSP primers 
are shown. The full first exon sequences as defined in GenBank are shown in caps. 
Transcriptional start sites as determined by 5′-RLM RACE in liver and the SV40 T-antigen 
immortalized nasopharyngeal epithelial cell line NP69 are marked with arrowheads. The 
translational start site (ATG) is boxed and individual CpG dinucleotides are shown in bold caps. 
MSP primer locations (DLC1-i4-M1/M2, U1/U2) are double underlined, whereas BGS primer 
locations (DLC1-i4-BGS1/2) are underlined with thick lines. (c) DLC1 isoform protein 
structures (not drawn to scale). The domain organization of all the DLC1 isoforms are shown 
with the sterile α motif, serine-rich domain, NLS, RhoGAP and START domain highlighted. 
The putative mitochondrial targeting sequence of DLC1-i4 is highlighted with a gray box. Name 
and amino-acid lengths of each isoform are shown on the left and right respectively. Curved bars 
denote coding exons. (d) Expression profile of all DLC1 isoforms in normal human adult and 
fetal tissues as assessed by semi-quantitative RT–PCR. The house-keeping gene GAPDH was 
used as a control. Underlined tissues were examined for DLC1-i4 silencing in their 




Table 2.1. Sequences of primers used in DLC1-i4 study. Abbreviations: DLC, 
deleted in liver cancer; MSP, methylation-specific PCR; RT–PCR, reverse transcription PCR. 
a Exon number according to Figure 2.1a. 
 We then cloned and sequenced the full-length 3,378 bp open reading 
frame (ORF) of DLC1-i4 from human liver RNA and identified a 1,125-aa open 
reading frame precisely matched with DLC1-i1 and -i2 except for a different 
short N-terminal region (Figure 2.1c and Supplementary Figure 2.1). Domain 
analysis showed the presence of domains typical of all the DLC members 
(Bernards, 2003; Ching et al., 2003; Durkin et al., 2007a) (Figure 2.1c). In 
addition, a putative mitochondrial targeting sequence was identified within the 
first 30 aa of DLC1-i4 using five online bioinformatics program, iPSORT, 
MitoProt II, Predotar, Mitopred and TargetP 1.1 server (Bannai et al., 2002; 
Claros and Vincens, 1996; Emanuelsson et al., 2007; Guda et al., 2004a; Guda 
et al., 2004b; Small et al., 2004). This sequence is coded by the unique first exon 
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of DLC1-i4 and is absent in other isoforms (Figure 2.1c and Supplementary 
Figure 2.1). 
 
Supplementary Figure 2.1.  Alignment of the amino acid sequences of three 
DLC1 isoforms, excluding isoform 3. The amino acid sequences of DLC1 isoform 1 
(1528 residues, NP_872584), isoform 2 (1091 residues, NP_006085) and isoform 4 were aligned 
using ClustalW2 and shaded using the BioEdit 7.0.1 program. Amino acid numberings are on 
the right, with dashes indicating gaps introduced to maximize amino acid identity. Identical 
residues are boxed. Location of the asterisk indicates the amino acid where the ORF coded for 
by the GenBank transcript AK025544 differs from the rest of the isoforms. Dotted box indicates 
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the putative mitochondrial localization signal predicted by five bioinformatics programs (iPsort, 
MitoProt II, Predotar, MitoPred and TargetP 1.1). 
 Genbank and Ensembl database searches querying the predicted aa 
sequence encoded by the new first exon found both full-length and partial 
mRNA transcripts coding for DLC1-i4 orthologs in mouse, rabbit, Rhesus 
macaque, cattle and elephant (Supplementary Figure 2.2). This cDNA was thus 
designated DLC1-i4 in accordance with the nomenclature used by GenBank. 
Due to a sequence variation in the previous cDNA sequence AK025544, in 
silico translation of this cDNA would yield a truncated protein of 804-aa up to 
the end of the RhoGAP domain (Supplementary Figure 2.1). With most of the 
available expression data on DLC1 isoform 2 only, we investigated the 
expression of all DLC1 isoforms including DLC1-i4 in human normal adult and 
fetal tissues by reverse transcription PCR (RT–PCR) using exon-specific 
primers to distinguish each isoform. All isoforms were detected in all normal 
tissues examined, with isoforms 2 and 4 showing stronger expression, and 





Supplementary Figure 2.2. Amino acid alignment of human DLC1-i4 and 
orthologs. (A) Amino acids alignment of human DLC1-i4 and orthologs present in mouse 
(Mus musculus, ENSMUSP00000096425), rabbit (Oryctolagus cuniculus, 
ENSOCUP00000001266), elephant (Loxodonta africana, ENSLAFP00000025484), Rhesus 
macaque (Macaca mulatta, XP_001092709) and cattle (Bos Taurus, NP_001095963). Amino 
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acid sequences were pulled out from either Ensembl or GenBank databases and aligned using 
ClustalW2 program and shaded using BioEdit program. Amino acid numberings on the right, 
dashes indicate gaps introduced to maximize amino acid identity. Dissimilar amino acid residues 
are boxed. Dashed box indicates amino acids coded for by unique first exon of DLC1-i4. (B) 
Phylogram of human DLC1-i4 and its orthologs identified in various mammalian species 
generated by ClustalW2. 
2.3.2 The functional DLC1-i4 promoter is up-regulated by p53 and stress 
We used bioinformatics screening to analyze ~3 Kb upstream of the putative 
DLC1-i4 promoter. A CpG-island of 1087 bp spanning the promoter, exon 1 and 
part of intron1 was found (Takai and Jones, 2003): GC content, 57%; 
observed/expected CpG ratio, 0.737; with a high concentration of 55 CpG sites 
in a 564-bp region (Figures 2.2a and 2.4a). Potential transcription factor (TF)-
binding sites predicted by three TF search programs (TFSEARCH, MotifSearch 
and MatInspector) suggest that the DLC1-i4 promoter might be regulated by 




Figure 2.2: Structure and functional localization of the DLC1-i4 promoter. 
(a) Structure of the DLC1-i4 5′-promoter region (Not drawn to scale). The enlarged diagram of 







Gray boxes with numbers below indicate exons. The transcriptional start site is labeled with an 
arrow. Putative binding sites of TP53, E2F, STATx and HSFs predicted by three different 
bioinformatics programs are labeled. Thick black bar shows the location of the CpG island. (b) 
Localization of the functional DLC1-i4 promoter using promoter luciferase assays. Promoter 
activities of three constructs containing different regions of the putative DLC1-i4 promoter 
relative to the promoter-less control vector using Luciferase assays are presented. Data shown 
are from three independent Luciferase assays (±s.d) in three cell lines (HEK293, CNE2 and 
HK1). Every one of the three different constructs of the DLC1-i4 promoter can drive the 
transcription of the target gene in all cell lines tested. (c) DLC1-i4 promoter is p53-responsive. 
The schematic diagram shows five putative p53-binding sites (BS) predicted by bioinformatics 
on the DLC1-i4 promoter. DLC1-i4 promoter construct were transfected into HEK293, CNE2 or 
HCT116/p53KO cell lines with (black bars) or without (shaded bars) TP53 expression construct, 
and assayed for luciferase activity after 48 h. Results of luciferase assays with respect to control 
pGL2 plasmid (open bars) in triplicates are shown in the histograms. The respective promoter 
constructs are shown on the left. Values on all histograms shown are the mean of three 
independent assays (±s.d). (d) Wild-type TP53, but not mutant TP53 is able to transactivate 
DLC1-i4 promoter activity. Wild-type or mutant p53 containing expression vectors were co-
transfected with either DLC1-i4 promoter construct (black bars) or pGL2-p21P (open bars) into 
the p53-null HCT116/p53KO cell line for 48 h before luciferase activity was measured. 
Histograms show DLC1-i4 promoter activity up-regulated by wild-type, but not mutant p53. The 
p21 promoter construct was used in parallel as a control for p53 transactivation. (e) TP53 up-
regulates DLC1-i4 promoter activity in a dose-dependent manner. Up-regulation of DLC1-i4 
promoter activity was observed with increasing amount of wild-type p53-expression vector. 
Increasing amount of the wild-type p53-expression vector (1 ng to 1 μg) was co-transfected 
together with either DLC1-i4 promoter construct (black bars) or pGL2-p21P (open bars) into 
HCT116/p53KO cell line. A two-tailed paired Student's t-test was performed to determine the 
statistical differences between the increasing p53 concentrations. Enh, enhancer. 
 Next, we evaluated whether the putative DLC1-i4 promoter was 
transcriptionally functional by cloning three fragments covering the promoter 
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separately into a promoter-less luciferase construct and transfected cell-lines 
with/without DLC1-i4 expression (HEK293, CNE2 and HK1). All three 
constructs could drive transcription, with the shortest fragment (−480/+140) 
showing the highest activity and the longest (−1840/+140) showing the lowest 
activity (Figure 2.2b), showing that the DLC1-i4 promoter is functional. 
 Bioinformatics analysis predicts that the DLC1-i4 promoter harbors five 
putative p53-binding sites (Figure 2.2a). To see whether p53 regulates this 
promoter, the promoter construct (pGL2-DLC1i4-PF1/R(−1840/+140)) with or 
without a p53 expression vector was transfected into HEK293, CNE2 and the 
p53-null HCT116/p53KO cells, and luciferase activity was assayed. p53 induced 
up-regulation of luciferase activity ranging from 3- to 38-fold, with the highest 
activity observed in HCT116/p53KO cells (Figure 2.2c). Co-transfection of 
DLC1-i4 promoter construct with mutant p53 expression plasmids (G245C and 
R248W) into HCT116-p53KO, showed that only wild-type p53 could 
upregulate DLC1-i4 and control p21 promoter activities (10-fold and 2.5-fold, 
respectively) (Figure 2.2d). As the p53 mutants are defective in DNA-binding 
(Bullock and Fersht, 2001; Zhou et al., 1999)\, this finding suggests that the 
ability of wild-type p53 to up-regulate DLC1-i4 promoter activity is attributed to 
its DNA binding ability. In addition, both gene promoters showed up-regulation 
of activity in response to increasing p53 concentration in a statistically 
significant (P<0.001–0.0015), dose-dependent manner up to 50 ng (Figure 2.2e) 
before dropping off at higher p53 concentrations. 
 We also transfected HCT116 or HCT116/p53KO cells with either the 
DLC1-i4 or the p21-promoter construct for 48 h before irradiation with 10 J/m2 
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of UV light and assayed for luciferase activity after 2–6 h incubation. Up-
regulation of either DLC1-i4 or p21 promoter activities was observed 
(Supplementary Figure 2.3), indicating that the DLC1-i4 promoter is stress-
responsive. 
 
Supplementary Figure 2.3. UV-induced p53 up-regulate DLC1-i4 promoter 
activity. After transfection with either DLC1-i4 promoter construct (black bars) or pGL2-p21P 
(open bars) for 48hrs, HCT116 and the p53-null HCT116/p53KO cells were UV irradiated at 
10J/m2 and further incubated for 2, 4 and 6 hours before luciferase assay. 
2.3.3 Promoter CpG methylation silences DLC1-i4 expression in multiple 
carcinoma cell lines 
As the functional DLC1-i4 promoter contains a CpG island, we assessed 
whether like DLC1-i2, DLC1-i4 is also silenced in tumors. The expression of 
DLC1-i4, together with -i1, -i2 and -i3, were examined by semi-quantitative 
RT–PCR in a panel of carcinoma cell lines, and we correlated DLC1-i4 
expression with its promoter CpG methylation using methylation-specific PCR 
(MSP) and bisulfite genomic sequencing (BGS). Results showed weak or no 
expression of DLC1-i4 transcripts in multiple carcinoma cell lines, including 2/4 
NPC, 8/16(50%) esophageal, 4/16(25%) gastric, 6/9(67%) breast, 3/4 colorectal, 
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4/4 cervical, 2/8(25%) lung carcinomas, as well as the various other cell lines 
tested (Figure 2.3 and Supplementary Figure 2.4). Meanwhile, strong 
methylated alleles were consistently detected in cell lines without DLC1-i4 
expression by MSP (Table 2.2, Figure 2.3 and Supplementary Figure 2.4). In 
contrast, DLC1-i4 was readily detected in all normal (HMEC and HMEpC) and 
normal immortalized cell lines (NP69, HEK293, RHEK1, NE1 and NE3) tested, 
with no methylated promoter alleles detected (Table 2.2 and Figure 2.3). High-
resolution BGS analysis performed for 55 CpG sites in the DLC1-i4 promoter 
(Figure 2.4a) validated the MSP data (Figure 2.4b). Collectively these results 
show that aberrant promoter CpG methylation is associated with DLC1-i4 
silencing, and like DLC1-i2, is a frequent event in multiple tumors. 
 
Figure 2.3: Expression analysis of all DLC1 isoforms and DLC1-i4 promoter 
methylation in multiple tumor cell lines and normal control. NPC, esophageal, 
gastric (GsCa), breast, colon, cervical, lung and hepatocellular carcinoma cell lines; 
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immortalized normal cell lines (NP69, HEK293, RHEK1, NE1 and NE3), normal epithelial cell 
lines (HMEC and HMEpC) and normal placenta tissue as controls. M, methylated; U, 
unmethylated. Fragment size indicated on right of panels. 
 
 





Supplementary Figure 2.4. Analysis of DLC1-i4 expression and promoter 
methylation in multiple carcinoma and lymphoma cell lines and PBMCs. (A) 
Lung, Hepatocellular (HCC), Gastric (GsCa) Renal (RCC), Prostate and Ovarian carcinoma cell 
lines; (B) Normal PBMCs, Burkitt lymphoma,  nasal natural killer (NK)/T-cell lymphoma and 
Hodgkin Lymphoma were assessed for DLC1-i4 mRNA expression and promoter methylation 
using RT-PCR and MSP. M: Methylated; U: Unmethylated. Fragment size indicated on right of 
panels. 
 DLC1-i1 and -i3 share a common promoter and their expression were 
silenced in almost all the tumor cell lines tested (Figure 2.3). Analysis on their 
shared CpG poor promoter through promoter luciferase assay showed that it is a 
transcriptionally functional promoter (Supplementary Figure 2.5A and 5B). 
Lack of TFs to drive the expression of DLC1-i1, -i3 and -i4 was unlikely, as all 
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promoter constructs were active in HK1, a cell line not expressing any DLC1 
isoforms (Figure 2.3). Further work is required to elucidate the mechanism of 
the silencing of DLC1-i1 and -i3. 
 However, unlike DLC1-i2, DLC1-i4 is not expressed in normal 
peripheral blood mononuclear cells (PBMCs) with no methylated alleles 
detected, but is expressed in normal lymph node (Figure 2.1d), indicating that 
mechanisms other than DNA methylation are involved in silencing of DLC1-i4 
promoter in normal PBMCs (Supplementary Figure 2.4B). This raised the 
possibility that different DLC1 isoforms might have functional specialization in 
different subsets of cells. Interestingly, DLC1-i4 is not expressed in any of the 
lymphoma cell lines tested (Supplementary Figure 2.4B), correlating with 





Supplementary Figure 2.5. Functional localization of the DLC1-i1 promoter 
and assessment of its tumor suppressive activity. (A) Schematic diagram of the 
location of 23 CpG dinucleotides along a 2,286 bp fragment of the 5’-promoter region including 
exon 1 of DLC1-i1. Vertical line represents one CpG site. Arrow denotes the transcriptional start 
site and box represents the first exon of DLC1-i1. (B) Localization of the functional DLC1-i1 
promoter via promoter luciferase assays. Promoter activities of three different regions of the 
putative DLC1-i1 promoter relative to the promoter-less control vector using luciferase assays 
are presented. Data shown are from three independent Luciferase assays (±s.d) in three cell lines 
(HEK293, CNE2 and HK1). Each of the three constructs of the DLC1-i4 promoter can drive the 
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transcription of the target gene in both cell lines tested. Enh: Enhancer. (C) HCT116 and HK1 
cells were transfected with pcDNA3.1(+) vector, pcDNA3.1(+)DLC1-i4 or pcDNA3.1(+)TP53 
and selected with G418. DLC1-i4 and TP53 greatly inhibited clonogenicity of tumor cells. 
2.3.4 Pharmacologic or genetic demethylation restores DLC1-i4 expression 
To determine whether CpG methylation is directly implicated in the silencing of 
DLC1-i4, two cell lines (C666-1 and HK1) with methylated and silenced DLC1-
i4 were treated with DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine 
(Aza). DLC1-i4 expression was restored after Aza treatment, although at 
different levels, with a concomitant increase in unmethylated promoter allele 
detected by MSP (Figure 2.4c). The same phenomenon was observed when 
HCT116, EC109 and HK1 were treated with Aza alone, or in combination with 
a histone deacetylase inhibitor trichostatin A (TSA) (Figure 2.4d). TSA 
treatment alone is insufficient to induce DLC1-i4 expression, implying a critical 
role for DNA methylation. Moreover, for HCT116 with genetic double 
knockout of both DNMT1 and DNMT3B genes (HCT116-DKO cell line)(Rhee 
et al., 2002), robust induction of DLC1-i4 RNA was accompanied by increased 
unmethylated DLC1-i4 alleles (Figure 2.4e). Weak DLC1-i4 expression with 
some demethylated alleles were also observed in DNMT1-knockout HCT116 
cells (HCT116-1KO), but knocking-out DNMT3B seems to have little effect on 
DLC1-i4 re-expression, even though weak demethylated alleles were also 
detected. Subsequent high-resolution BGS methylation analysis confirmed the 
substantial demethylation of DLC1-i4 promoter in HCT116-DKO cells, 
indicating that the DLC1-i4 promoter methylation is cooperatively maintained 




Figure 2.4: DLC1-i4 is silenced by DNA methylation in carcinoma cell lines 
and demethylation by pharmacological or genetic approach could induce 
DLC1-i4 re-expression. (a) Schematic diagram of the location of 59 CpG dinucleotides 
along an 800 bp fragment encompassing exon 1 on the 5′-promoter region of DLC1-i4. Vertical 
line represents one CpG site. Locations of CpG sites 1–55 examined by high-resolution 
methylation analysis are demarcated by the horizontal bracket. Arrow denotes the transcriptional 
start site and box represents the first exon of DLC1-i4. Gray block arrows indicates location of 
MSP primers. (b) High resolution mapping of individual CpG sites on the DLC1-i4 promoter in 
tumor and normal cell lines as assessed by BGS. A 564 bp fragment of the core promoter 
containing 55 CpG sites was analyzed using dideoxynucleotide sequencing. CpG site is shown 
on top with numbered ballooned arrows. Gray block arrows denote MSP primers location. 
Methylation status of individual CpG site is expressed as percentage methylation calculated 
from 5–12 sequenced colonies. Number of clones sequenced, MSP and RT–PCR expression 
results are shown on the right. (c) Demethylation by Aza restores DLC1-i4 expression in Aza-
treated NPC cell lines C666-1 and HK1 (day 3 (72 h) or day 6 (144 h)) with concomitant 
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demethylation of its promoter. (d) Re-expression of DLC1-i4 can only be mediated by Aza alone 
(72 h) or combined with TSA (96 h). (e) Genetic double knockout of both DNMT1 and DNMT3B 
strongly induces DLC1-i4 promoter demethylation and mRNA expression. (f) High-resolution 
methylation mapping of 55 CpG sites in a 564 bp region of the DLC1-i4 promoter by BGS 
confirmed the genetic demethylation in HCT116-DKO. Horizontal line represents the DLC1-i4 
promoter region with short vertical lines representing each CpG site analyzed. Percentage 
methylation was established as total percentage of methylated cytosines from 5–12 randomly 
sequenced colonies. Numbers of clones sequenced, MSP and RT–PCR expression results are 
shown on the right. The locations of MSP primers are indicated by thick gray arrows. M, 
methylated; U, unmethylated. +, expressed; −, silenced. 
2.3.5 Promoter methylation and expression of DLC1-i4 in multiple primary 
carcinomas 
DLC1-i4 methylation was next examined in multiple primary tumors, including 
NPC, esophageal, gastric, hepatocellular, breast and colorectal carcinoma. We 
first examined DLC1-i4 methylation in nine normal nasopharynx tissues and 
found weak methylation in only three (33%) (Figure 2.5a and Table 2.2), 
meanwhile, methylation was detected in 48/49 (98%, with two weakly 
methylated) endemic NPC tumors from Asian Chinese (Figure 2.5a and Table 
2.2), and in 14/30 (47%) esophageal carcinomas but less frequently in the paired 
non-tumor tissues (Figure 2.5c and Table 2.2). In addition, DLC1-i4 methylation 
was detected in 9/11 (82%) primary gastric, 10/13 (77%, with two weakly 
methylated) breast, 14/37 (38%) HCC and 11/11 (100%) colorectal carcinomas 
(Figure 2.5c and Table 2.2). RT–PCR and MSP analysis of primary NPC 
showed down-regulation of DLC1-i4 expression in 5/9 specimens but weak 
correlation of DLC1-i4 expression with methylation of DLC1-i4 promoter 
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(Figure 2.5b). RT–PCR analysis of matched breast primary tumor and adjacent 
normal tissue showed DLC1-i4 downregulation in the tumor as compared with 
the matched normal tissue (Figure 2.5d). These results indicate that DLC1-i4 
methylation occurs frequently in tumors and affects DLC1-i4 expression. 
 
Figure 2.5: Promoter methylation of DLC1-i4 in multiple primary 
carcinomas. Representative MSP data showing methylation of DLC1-i4 in multiple primary 
tumors but not in normal nasopharynx and matched tissues. (a) Normal nasopharynx tissues as 
controls and primary NPC tumors from Asians. (b) Expression of DLC1-i4 and MSP in a subset 
of primary NPC tumors. (c) Methylation in multiple primary carcinomas. (d) DLC1-i4 
expression in matched breast primary tumor and normal tissue pair. M, methylated; U, 
unmethylated; N, paired surgical marginal tissues; T, tumor tissues. 
2.3.6 DLC1-i4 suppresses tumor cell colony formation 
To examine the effects of DLC1-i4 on tumor cell growth, we transfected a 
DLC1-i4 expression construct into HCT116, HK1 and KYSE510 cell lines, all 
of which have methylated and silenced endogenous DLC1-i4, and the 
clonogenicity of transfected cells was assessed by monolayer culture. 
Significant reduction in colony numbers were observed in all cell lines tested 
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(down to ~24–44% of vector control, P<0.001) (Figures 2.6a and 2.6b), similar 
to that by TP53 (data not shown). Thus, DLC1-i4 is a functional tumor 
suppressor having growth inhibitory activities in tumor cells. As DLC1-i1 shares 
structural domains with DLC1-i4 and DLC1-i2, we tested DLC1-i1 in the same 
assay and showed that DLC1-i1 is also a functional tumor suppressor 
(Supplementary Figure 2.5C). 
 
Figure 2.6: Ectopic expression of DLC1-i4 suppresses clonogenicity of 
carcinoma cells. (a) Colorectal carcinoma (HCT116) and esophageal carcinoma (KYSE510) 
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cell lines were transfected with pcDNA3.1(+) vector alone, pcDNA3.1(+)DLC1-i4 or 
pcDNA3.1(+)TP53 and selected with G418. DLC1-i4 and TP53 greatly inhibited clonogenicity 
of tumor cells. Control cells without vector would not survive G418 selection. (b) Quantitative 
analyses of colony numbers of HCT116, KYSE510 and NPC cell line HK1. Number of G418-
resistant colonies in vector-only transfected cell line was set as 100%. Values are the mean±s.e. 
from three independent experiments. Asterisk indicates statistically significant difference 
(**P<0.001). 
2.4 Discussion 
DLC1 is a well-defined bona fide tumor suppressor, frequently silenced in 
multiple tumors (Goodison et al., 2005; Ng et al., 2000; Seng et al., 2007; Yuan 
et al., 1998; Yuan et al., 2003). This gene is transcribed from two different 
promoters, resulting in transcripts encoding three insofar known isoforms. To 
date, virtually all studies have focused on only one of them—the prototype 
DLC1-isoform 2. From our previous work on DLC1 in carcinoma (Seng et al., 
2007) we identified a fourth isoform of DLC1. In this report, we provide 
evidence that this novel isoform 4 (DLC1-i4) codes from an alternative promoter 
a 1125-aa protein, which differs from DLC1-isoforms 1 and 2 at the extreme N-
terminal because of the use of an alternative first exon, but nevertheless share 
the rest of the exons common to both isoforms and thus have the same protein 
domain structure. In addition, the protein sequence of DLC1-i4 was found to 
contain a mitochondrial targeting sequence in its first 30 aa coded for by the 
new first exon, a signal missing from the rest of the DLC1 isoforms. The 
possible mitochondria localization of DLC1-i4 however awaits further 
confirmation. With the variability at the N-terminal region of DLC1-i1, -i2 and -
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i4, it may be inferred that the conserved C-terminal region domains are critical 
in mediating specific protein–protein interactions. 
 Similar to DLC1-i2, the DLC1-i4 promoter is hypermethylated in 
multiple tumor types including NPC, esophageal, gastric, breast, colorectal, 
cervical and HCC cell lines and primary tumors, which is associated with 
transcriptional silencing. Methylation-mediated silencing could be reversed 
pharmacologically or by genetic double knockout of DNMT1 and DNMT3B. In 
addition, ectopic-DLC1-i4 expression in carcinoma cells shows tumor 
suppressive properties. In contrast, no methylation or silencing was detected in 
any of the immortalized normal cell line controls tested, indicating that DLC1-i4 
methylation probably occurs late in carcinogenesis. The correlation between 
promoter methylation and gene expression in primary tumor will require further 
characterization in tumors other than NPC, as the presence of large proportions 
of non-malignant stromal cells in NPC tumors makes clear delineation of gene 
expression difficult. 
 The use of alternative promoters and exon skipping to generate 
transcripts with different 5′-ends appear to be common among the DLC family 
of RhoGAPs. DLC2, a gene homologous to DLC1 at 13q12.3, yields four 
different transcripts to generate four protein products of differing lengths (Leung 
et al., 2005). DLC3 at Xq13 was found to yield three transcripts generated by the 
same means (Durkin et al., 2007a). Similar type of regulation (alternative 
promoters and exon variability) are also found in other TSGs, for example, 
TP53, APC and BRCA1 (Bourdon et al., 2005; Horii et al., 1993; Xu et al., 
1995), and is associated with the generation of proteins with different functional 
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properties. Our data and others show that DLC1 encode four major isoforms 
from three alternative promoters. Interestingly, it was recently verified by 3′-
RACE in mouse that a 6.2 Kb transcript found in the Vega database is indeed 
expressed and probably codes for a 127 kDa protein with a sequence nearly 
identical to DLC1-i4 (Sabbir et al., 2010). The complexity and expression of 
different DLC1 transcripts may be a way of differential regulation to cater for 
different functions of each isoform. 
As the tissue expression pattern of DLC1-i1 and -i3 transcripts is controversial, 
we addressed this question using isoform-specific primers and RT–PCR to 
check their expression in a panel of normal adult and fetal tissues. Our results 
show that all DLC1 isoforms are expressed at different levels and they have an 
overlapping ubiquitous expression pattern in all normal tissues tested, except 
that only DLC-i2 is expressed in PBMCs. Our work on the common promoter of 
DLC-i1 and -i3 demonstrated that it is a functional promoter, and the full-length 
open reading frame of DLC1-i1 does have tumor suppressor function. DLC1-i3 
is unlikely to have tumor suppressor activity as it does not harbor the canonical 
DLC1 domains and so was not tested. The speculation that DLC1-i3 is a 
regulator of other DLC1 isoforms remains to be verified. Our findings are 
corroborated by a recently published study in which DLC1β (-DLC1-i1) and 
DLC1α (DLC1-i2) but not DLC1γ (DLC1-i3) were shown to suppress stress 
fiber formation and HCC cell growth (Ko et al., 2010). It is noteworthy that both 
isoforms are almost totally silenced in all tumors and immortalized normal cell 
lines tested, but the silencing mechanism is unclear as this promoter is not a 
CpG island, and could not be activated by Aza treatment (unpublished 
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observation). Taken together, the data suggest that different DLC1 isoforms may 
have different functional specialization in cellular homeostasis and oncogenesis, 
and whether they are functionally redundant or not still needs further exploration. 
 p53 is an important tumor suppressor, mutated in ~50% of all cancers 
(Efeyan and Serrano, 2007). DLC1-i4 promoter harbors at least five putative p53 
binding sites; and our data showed that it is up-regulated by wild-type p53, 
requiring the DNA-binding ability of p53. UV treatments also moderately up-
regulated this promoter, similar to the p21 promoter, indicating that the DLC1-i4 
promoter is p53-regulated. 
In summary, we identified a new isoform of DLC1, transcribed from an 
alternative promoter. This novel isoform, designated DLC1-i4, was found to 
have tumor inhibitory properties, silenced epigenetically in multiple carcinomas 
and regulated by the p53 tumor suppressor. Although several important issues 
remain to be addressed, such as the functional overlap of each individual DLC1 
isoforms, the frequent deregulation of DLC1-i4 in multiple tumors indicates that 
it may be an important tumor suppressor.  
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Chapter 3: Investigation of an 11q13 tumor suppressive locus in 
a nasopharyngeal carcinoma (NPC) cell line identified NPAS4 as 
a candidate tumor suppressor silenced by promoter DNA 
methylation in NPC and other tumors
 
3.1 Introduction 
Nasopharyngeal carcinoma (NPC) is a common tumor in ethnic Chinese in 
Southern China and South Asia (Lo et al., 2004; Tao et al., 2006; Tao and Chan, 
2007). Stepwise inactivation of tumor suppressor genes (TSGs) and 
mobilization of mutant oncogenes are common events in cancer development 
and genetic predisposition, environmental factors and the Epstein-Barr virus are 
all believed to be involved in NPC pathogenesis (Hanahan and Weinberg, 2011; 
Lo et al., 2004; Tao et al., 2006; Tao and Chan, 2007).  
 It was demonstrated using monochromosome transfer approaches that 
two potential tumor suppressor critical regions (CRs) are localized at 
chromosome region 11q13 and 11q22-23 in the NPC HONE1 cell line (Cheng et 
al., 2000). The NPC tumor-suppressive CRs was further refined to a 1.8-
megabase (Mb) region within 11q13 and 3 other regions within 11q22-23 using 
FISH and microsatellite typing (Cheng et al., 2002; Lung et al., 2008). The 
presence of important TSGs relevant in NPC was later confirmed with the 
cloning of the cell adhesion molecule 1 (CADM1)(Lung et al., 2004) and alpha 
B-crystallin (CRYAB)(Lung et al., 2008) at 11q23.2, with the former 
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subsequently shown to be involved in other tumors as well (Chen et al., 2011; 
Steenbergen et al., 2004; Takahashi et al., 2011; Yang et al., 2011). However no 
TSG relevant in NPC has been identified on 11q13 to date. 
 The 1.8Mb CR within 11q13 was suggested to harbor at least one 
candidate TSG relevant in NPC mapping between the microsatellite marker 
D11S4907 and the gene GSTP1 (Cheng et al., 2002). However the transcript 
levels of the multiple endocrine neoplasia type 1 (MEN1) gene, a known TSG 
located 80kb proximal of the 1.8Mb CR was found normal and hence not 
suggested to play a role in NPC (Cheng et al., 2002). Studies conducted by 
various groups revealed that other than NPC, sequences present in 11q13 are 
also frequently deleted in cervical, breast, endocrine, head and neck and other 
tumors (Chakrabarti et al., 1998; Hui et al., 1996; Sirchia et al., 2000; Srivatsan 
et al., 2000; Venugopalan et al., 1998; Zhuang et al., 1995). In addition, LOH 
studies in some tumor types found tumor suppressive CRs overlapping with the 
1.8 Mb NPC CR suggesting that candidate genes found in this region may serve 
as a tumor suppressor in multiple tumor types (Chakrabarti et al., 1998; 
Srivatsan et al., 2000; Srivatsan et al., 2002; Zainabadi et al., 2005). Of note, 
extensive studies conducted by Mendonca et al. using the HeLa cell-derived 
CGL1 radiation-induced neoplastic transformation model suggested that the 
TSG(s) present in 11q13 may be involved in transcriptional regulation 
(Mendonca et al., 1999; Mendonca et al., 2004). Taken together, these studies 
suggest there is at least one TSG located in 11q13 between the markers 




 The existing evidences prompted an attempt to elucidate the source of 
this tumor-suppressive activity on 11q13 in NPC. Thorough examination of the 
1.8Mb region revealed 68 genes between the markers D11S4907 and GSTP1 
and identified ten putative and confirmed transcriptional regulators (FOSL1, 
DRAP1, BRMS1, NPAS4, BBS1, ZDHHC24, KDM2A, RAD9A, AIP and 
CDK2AP2) (Table 3.1). Through reverse transcription-PCR (RT-PCR) 
expression analysis on the NPC HONE1 and cervical carcinoma HeLa cell lines, 
we confirmed that only neuronal PAS domain protein 4 (NPAS4) was down-
regulated in HONE1.  
 NPAS4 is a novel transcription factor of 802 amino acid long and 
showed high homology with the basic helix-loop-helix PER-ARNT-SIM 
(bHLH-PAS) family; members of which are involved in a wide range of 
physiologic and developmental events (Canaple et al., 2003; Fu and Lee, 2003; 
Kewley et al., 2004; Ooe et al., 2004). Many proteins regulating the mammalian 
circadian rhythm contain the bHLH-PAS motif, suggesting that this motif may 
define an evolutionarily conserved feature of the circadian clock mechanism 
(Canaple et al., 2003; Kewley et al., 2004). NPAS4 is also able to interact with 
the aryl hydrocarbon nuclear translocator (ARNT) and also aryl hydrocarbon 
receptor nuclear translocator-like (ARNTL) (Ooe et al., 2004). The ARNTL gene, 
together with CLOCK, are prominent members of the bHLH-PAS domain 
containing family whose disruption will cause alterations in the behaviour 
rhythmicity in rodents and contribute to tumorigenesis; defining their 
importance in the regulation of the circadian rhythm (Canaple et al., 2003; Fu 
and Lee, 2003; Kewley et al., 2004). The period homolog 2 (PER2) gene is a 
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notable example shown to function in tumor suppression whose silencing causes 
retardation to the DNA damage responsive pathway (Chen-Goodspeed and Lee, 
2007; Fu and Lee, 2003; Lee, 2006). 
 In this study, we demonstrate that NPAS4 is down-regulated in multiple 
carcinoma cell lines as well as primary tumor tissue and that promoter DNA 
methylation has a role to play in the silencing of this gene. NPAS4 was also 
found to be up-regulated after Ultra-Violet (UV) light irradiation and 
Adriamycin drug treatment, suggesting a role in the DNA damage pathway. 
Finally, ectopic expression of NPAS4 in silenced cell lines is shown to exert a 
strong inhibitory effect on cell growth and clonogenicity. This is the first report 
documenting NPAS4 as a candidate tumor suppressor, its inactivation by 
promoter DNA methylation and its possible role in the DNA damage response. 
  
3.2 Materials and Methods 
3.2.1 Cell Lines and normal tissue samples 
Cell lines used were: 5 NPC (C666-1, CNE-1, HK1, HNE1 and HONE1) 
(Glaser et al., 1989; Qiu et al., 2004; Ying et al., 2005), 2 colorectal (HCT116 
and HT-29)(Cui et al., 2008), 5 lung (A427, A549, H292, H358 and H1299)(Cui 
et al., 2008) 16 esophageal (EC1, EC18, EC109, HKESC1, HKESC2, HKESC3, 
KYSE30, KYSE70, KYSE140, KYSE150, KYSE180, KYSE270, KYSE410, 
KYSE510 and KYSE520)(Cui et al., 2008; Tang et al., 2001; Ying et al., 2006), 
9 breast (BT549, MDA-MB-231, MB468, MCF7, SK-BR-3, T47D, YCC-B1, 
YCC-B3 and ZR-75-1)(Cui et al., 2008; Kim et al., 2005; Ying et al., 2005) and 
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6 gastric carcinoma (SNU719, AGS, MKN28, MKN45, SNU1 and 
SNU16)(Steenbergen et al., 2004; Ying et al., 2006). Four immortalized normal 
epithelial cell lines (NP69, NE1, NE3, and RHEK-1)(Qiu et al., 2004; Ying et 
al., 2005) with many features of normal epithelial cells together with the human 
embryonic kidney cell line HEK293 were used as normal controls (Lee et al., 
2008). HCT116 DNMT1-/- (1KO), HCT116 DNMT3B-/- (3BKO), and HCT116 
DNMT1-/-DNMT3B-/- (DKO) cells are gifts from Bert Vogelstein (Johns 
Hopkins, MD, USA). Cells lines are maintained in RPMI or DMEM medium 
supplemented with 10% fetal bovine serum (FBS) or Keratinocyte SFM 
Medium (for NP69 only) (Lo et al., 2006; Tsao et al., 2002). Total RNA and 
DNA were extracted from cell pellets using TRI Reagent (Molecular Research 
Centre Inc., OH, USA) as reported previously (Tao et al., 2002b). Human 
normal adult and fetal tissue RNA samples were purchased commercially (Seng 
et al., 2007; Ying et al., 2006). DNA samples of primary NPC, esophageal 
carcinoma, breast carcinoma and gastric tumors have been described previously 
(Cheng et al., 2010; Cui et al., 2008; Shu et al., 2011) 
3.2.2 Semi-quantitative RT-PCR 
RT–PCR was performed as previously described using the Taq-Gold 
polymerase and the GeneAmp RNA PCR system (Applied Biosystems, CA, 
USA), with GAPDH as a control (Tao et al., 2002b). All RT-PCR was 
performed with 35 cycles except GAPDH (25 cycles). Primer sequences are 




3.2.3 5' RLM-RACE 
5′-RLM-RACE was done with normal trachea RNA (BD Clontech, Palo Alto, 
CA, USA), using the FirstChoice RLM-RACE kit (Ambion Inc., TX, USA) 
according to the manufacturer's protocol. First, reverse transcription was 
performed first with random hexamers and the cDNA used for nested PCR to 
amplify the 5′ end of NPAS4 with kit provided sense primers and NPAS4 
specific antisense primers (Primer sequences available in Table 3.2). Nested 
PCR amplification was carried out in a 25 μl volume consisting of 1 μl of cDNA, 
0.6 U of AmpliTaq Gold (Applied Biosystems, CA, USA), 0.6 μM of each 
primer, and 2 mM MgCl2. The amplification cycle involve an initial ‘hot start’ at 
95 °C for 10 min, followed by 35 cycles of amplifications (94 °C, 30 s; 55 °C, 
30 s; 72 °C, 2 min) with a final extension step of 72 °C for 10 min. Nested PCR 
reaction was diluted 10 × with sterile water and 1 μl of the diluted reaction was 
used for subsequent nested PCR with the same conditions. PCR products were 
analyzed on 2% agarose gels. Bands were excised and TA-cloned and 3 colonies 
were randomly chosen and sequenced with the ABI PRISM BigDye v1.1 Kit 
(Applied Biosystems, CA, USA). 
3.2.4 Bioinformatics analysis 
Genes, microsatellite markers, NPAS4 gene and amino acid (aa) sequences were 
obtained from GenBank (www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD= 
search&DB=gene)(Maglott et al., 2007). Location of CpG island was predicted 
with CpG Island Searcher (www.uscnorris.com/cpgislands2/cpg.aspx)(Takai 
and Jones, 2002; Takai and Jones, 2003) using default settings. TF-binding sites 
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on NPAS4 promoter predicted with TFSEARCH 
(www.cbrc.jp/research/db/TFSEARCH.html) (Akiyama, 1995; Heinemeyer et 
al., 1998), MotifSearch (www.motif.genome.jp/) (Heinemeyer et al., 1999) and 
MatInspector (www.genomatix.de)(Cartharius et al., 2005). 
3.2.5 Promoter reporter assays and plasmid construction 
Three different regions of the putative NPAS4 promoter were PCR amplified 
from normal placenta DNA (Sigma-Aldrich Corporation, St Louis, MO, USA) 
using a high-fidelity DNA polymerase Kapa HiFi (Kapa Biosystems, MA, USA), 
RE digested and ligated into the promoterless firefly luciferase pGL4.11[luc2P] 
Vector (Promega, WI, USA) to create pGL4-NPAS4-PF2/PR1(-2614/+196), 
pGL4-NPAS4-PF3/PR1(-1493/+196) and pGL4-NPAS4-PF4/PR1(-639/+196). 
The NPAS4 expression vector with a Hemagglutinin (HA) tag at its N-terminus 
and its ATG ‘start’ codon within a Kozak consensus sequence (Kozak, 1986; 
Kozak, 1987) was constructed by PCR amplification from human fetal brain 
cDNA (Clontech, CA, USA) using the Phusion high-fidelity DNA polymerase 
(Finnzymes, Espoo, Finland) restriction enzyme (RE) digested and ligated into 
pcDNA3.1(+) expression vector (Invitrogen, CA, USA) to form pcDNA3.1(+)-
NPAS4. pcDNA3.1(+)TP53 was constructed by sub-cloning the full-length 
wild-type TP53 from plasmid pC53-SN (gift from Dr Bert Vogelstein) into 
pcDNA3.1(+). 
 Plasmids were prepared and purified using the Endofree Plasmid Maxi 
Kit from Qiagen (Qiagen GmbH, Germany). Promoter activities were tested by 
co-transfection of cell lines (HONE1, C666-1 and HCT116) in 12-well plates 
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with 2 μg of promoter construct and 50 ng of Renilla Luciferase plasmid pRL-
SV40 as an internal control using Fugene 6 (Roche Diagnostics, Mannheim, 
Germany). Transfected cells were grown for 48 h before luciferase assay using 
the Dual Luciferase Reporter Assay System (Promega). Three independent 
assays were conducted and the mean±s.d. values were calculated. To assess 
whether NPAS4 autologously regulate its own promoter, cell lines (HCT116 and 
C666-1) were transfected with or without 100ng of pcDNA3.1(+)-NPAS4 
together with 2 μg of pGL4-NPAS4-PF2/PR1(-2614/+196) promoter construct 
and 50 ng of pRL-SV40 and assayed as described previously.  
3.2.6 DNA bisulfite treatment and promoter methylation analysis 
Bisulfite modification of DNA and the subsequent MSP and BGS analyses were 
previously described (Tao et al., 1999b; Tao et al., 2002b). MSP and BGS 
primer sets are listed in Table 3.2. All primer sets were previously tested for not 
amplifying any unbisulfited DNA. For BGS, the PCR products were gel-purified, 
excised and TA-cloned into the pCR2.1-TOPO vector (Invitrogen, CA, USA) 
and 5–12 colonies were randomly chosen and sequenced. All PCR reactions 
were carried out using the AmpliTaq-Gold DNA polymerase for 40 cycles with 
"hot start" (Applied Biosystems, CA, USA). 
3.2.7 Drug and ultra-violet (UV) light treatment 
For 5-aza-2'-deoxycytidine (Aza) treatment, cells were freshly seeded at a 
concentration of 1 x 105 cells per ml in T-75 flasks and allowed to grow 
overnight with fresh medium containing Aza (Sigma, St. Louis, MO) at a final 
concentration of 10 μM. The Aza treatment is continued for 72 h with fresh Aza-
 70 
 
medium changed every 24h and subsequetly the cells are harvested for DNA 
and RNA extraction. For trichostatin A (TSA)(Sigma, St. Louis, MO) treatment, 
cells were treated as above for 72 h using 10 μM of Aza and subsequently with 
medium containing100 ng/ml TSA only for another 24 h before harvesting. 
 Drug induced DNA damage was performed by treating cells with 
medium containing 0.5µg/ml of Adriamycin (Adr) for 24 h or 1µg/ml Adr for 6, 
10 and 24 h respectively before harvesting for DNA and RNA extraction. For 
UV treatment, cells are seeded and allowed to grow to 70 - 80% confluency in a 
100mm dish for 24 h. After incubation, the growth medium was removed and 
stored and cells were washed with 1x PBS before irradiation with 30 J/m2 UV in 
a Stratalinker UV Crosslinker 1800 (Stratagene, CA, USA). After UV 
irradiation, original growth media was replaced and cells are incubated for a 
further 2–24 h before harvesting for DNA and RNA. 
3.2.8 Real-Time PCR 
Total RNA was prepared from Adr or UV-treated tumor cell line samples using 
TRI Reagent (Molecular Research Centre Inc., Cincinnati, OH, USA) as 
previously described (Tao et al., 2002a). cDNA was then synthesized by reverse 
transcription of total RNA using GeneAmp RNA PCR system (Applied 
Biosystems, CA, USA) according to the manufacturer's protocol. Real-time 
quantitative RT-PCR with SYBR green was performed using Power SYBR 
Green PCR master mix (Applied Biosystems, CA, USA) in an ABI7500 Fast 
Real Time PCR System (Applied Biosystems, CA, USA). The expression levels 
of NPAS4 and CDKNA1 (positive control for DNA damage response) transcripts 
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measured by quantitative real time PCR were adjusted by the transcript 
expression level of GAPDH which served as an internal standard. Primer 
sequences are available in Table 3.2. PCR was carried out using 10 µl of power 
SYBR® Green PCR master mix (Applied Biosystems, CA, USA) with 200 nM 
each of forward and reverse primers and 50 ng of cDNA topped up with water to 
a final volume of 20 µl. The PCR conditions were as follows: 50°C for 2 min, 
95°C for 10 min and 40 cycles of 95°C for 15 s and 60°C for 1 min. 
3.2.9 Chromatin Immunoprecipitation (ChIP) 
The colorectal carcinoma cell line HCT116 was used in this study as it was 
previously shown to harbor functional endogenous wild-type (wt) p53 gene (Yu 
et al., 1999). ChIP was carried out using a ChIP assay kit according to the 
manufacturer's protocol (Cat# 17-295, Upstate, NY, USA). Briefly, cells before 
and after Adr treatment (16 h) and UV irradiation (20 h) were crosslinked with 
1 % formaldehyde for 10 min at room temperature. Excess formaldehyde was 
inactivated by addition of 125 mM glycine. After centrifugation the cell pellets 
were rinsed twice with ice-cold phosphate buffered saline (PBS) and then 
suspended in SDS lysis buffer supplemented with protease inhibitors. The lysate 
was subjected to sonication on ice with a Branson sonicator for 8 cycles 
(consisting of 10 secs ON, 30 secs OFF per cycle) at 30% power. Sonicated 
chromatin containing DNA fragments of 500 bp on average was pre-cleared 
with salmon sperm DNA protein A agarose before immunoprecipitation using 
anti-p53 DO1 monoclonal antibody (Santa Cruz, CA, USA) overnight at 4°C. 
Immunoprecipitated chromatin were washed sequentially in low salt, high salt, 
lithium chloride and finally twice with TE buffers then eluted in SDS elution 
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buffer. The protein/DNA crosslink was reversed at 65°C for 4 h the treated with 
Proteinase K for 1 h before clean-up using phenol/chloroform extraction and 
ethanol precipitation. Purified DNA was dissolved in nuclease-free water and 
used for PCR using primers targeting putative p53 binding sites (primer 
sequences available in Table 3.2) on the NPAS4 gene and PCR products were 
subjected to agarose gel electrophoresis and visualize in an UV illuminator. 
3.2.10 Colony formation and stable transfectant selection  
HCT116 and HONE1 cells (3 × 105 cells per ml) were plated in a 12-well plate 
and grown for 24 h before transfection with 2 μg of either NPAS4 or p53 
expression plasmids or empty vector using Fugene 6 (Roche Diagnostics, 
Mannheim, Germany) according to the manufacturer's protocol. At 48 h post-
transfection, transfected cells were trypsinized and diluted into 6-well plates 
with G-418 (HCT116: 500 μg/ml; HONE1: 800 μg/ml) selection for 2–3 weeks. 
Surviving colonies (with >50 cells per colony) were fixed with methanol and 
stained with Gentian Violet before being counted. The experiment was repeated 
thrice independently and the results are expressed as values of mean ± SE. 
Statistical analysis was carried out with Student’s t test with P < 0.05 considered 
as being statistically significant. At 48 h post transfection, a parallel set of 
transfected cells were plated into 10-cm dishes to establish stable transfectants. 
Surviving colonies after selection in G418 for at least 3 weeks were isolated and 
expanded for further analysis. Stable clones found expressing NPAS4 after RT-




3.2.11 Cell proliferation assay  
To monitor cell proliferation, 1000 cells of HONE1 stable clone were plated in 
96-well plates and incubated at 37°C in selective media for 24, 48, 72 and 96 h. 
At the end of each time-point, the number of viable cells were determined by the 
3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) (Promega, 
WI, USA) assay. 
3.2.12 Wound healing assay 
To assess the effect of NPAS4 on cellular mobility, a scratch wound assay was 
performed on stably transfected HONE1 cells. Cells were cultured in 24-well 
plate until confluent and the cell layer carefully scratched with sterile pipet tips 
to create a wound. Wounded cell layers were incubated for 6 and 24 h and 
photographed at 4x magnification at each time-point. Experiments were 




3.3.1 NPAS4 is ubiquitously expressed in normal tissues but down-
regulated in the 11q13 1.8Mb tumor suppressor CR 
Studies suggest that the 1.8Mb tumor suppressive CR between the markers 
D11S4907 and GSTP1 in 11q13 contains at least one candidate TSG functioning 
as a transcriptional regulator (Cheng et al., 2002; Mendonca et al., 1999; 
Mendonca et al., 2004). The tumor suppressor CR was scrutinized and 68 genes 
were found residing between D11S4907 and GSTP1; from which ten 
putative/confirmed transcriptional regulator were identified (Table 3.1). 
No.  Gene  Official Full Name  Brief Summary 
1)  FOSL1  FOS‐like antigen 1  Encode leucine zipper proteins. Can dimerize with JUN family 
proteins to form AP‐1 transcription factor. 
2)  DRAP1  DR1‐associated  protein  1 
(negative cofactor 2 alpha) 
Encode  a  co‐repressor  of  transcription  that  interacts  with 
DR1 to enhance DR1‐mediated repression. 







involved  in  a wide  range  of physiologic  and developmental 
events. 
5)  BBS1  Bardet‐Biedl syndrome 1 Protein may play a role in eye, limb, cardiac and reproductive 
system development. 




7)  KDM2A  lysine  (K)‐specific 
demethylase 2A 
Protein specifically demethylates histone H3 at lysine‐36. 
8)  RAD9A  RAD9 homolog A (S. pombe) Protein  highly  similar  to  S.  pombe rad9,  a  cell  cycle 
checkpoint  protein  required  for  cell  cycle  arrest  and  DNA 
damage repair. 
9)  AIP  aryl  hydrocarbon  receptor 
interacting protein 
Encodes  a  receptor  for  aryl  hydrocarbons  and  a  ligand‐
activated transcription factor. 





Table 3.1. Putative/confirmed transcriptional regulator gene candidates 





Figure 3.1. NPAS4 is silenced in the 11q13 critical region for tumor 
suppression in HONE1 cells as assessed by semi-quantitative RT-PCR. The 
house-keeping gene GAPDH was used as a loading control. 
 Our lab was interested in genes silenced via promoter DNA methylation 
also and using an RT-PCR approach, we interrogated the HONE1 and HeLa cell 
lines before and after treatment with 5-aza-2'-deoxycytidine (Aza) using primers 
targeting the ten putative/confirmed transcriptional regulator (primer sequences 
in Table 3.2). Out of the ten genes assayed, only NPAS4 was silenced in HONE1 
cells and Aza treatment was able to induce re-expression of this gene; 
suggesting an epigenetic inactivation mechanism (Figure 3.1). Interestingly, 
NPAS4 was strongly expressed in HeLa and three other cervical carcinoma cell 
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lines (Figure 3.1 and data not shown) which may either suggest that NPAS4 may 
not play a tumor suppressor role in cervical carcinoma or other mechanisms of 
inactivation may be involved (i.e. mutation). Further work is necessary to 
determine the role of NPAS4 in cervical carcinoma. 
 We then cloned and sequenced the full-length 2,409 bp open reading 
frame (ORF) of NPAS4 from human fetal brain RNA and confirmed a 802 
amino acid protein coding region; in agreement with the nucleotide and protein 
sequences deposited in GenBank (Acession no.: NM_178864 and NP_849195) 
(Maglott et al., 2007). Amino acid analysis showed the presence of a basic 
helix-loop-helix (bHLH) motif, a PER-ARNT-SIM (PAS) domain and a 
transcription activation domain (TAD) typical of the bHLH-PAS domain 
containing family of transcription factors (Figure 3.2A) (Chen-Goodspeed and 
Lee, 2007; Fu and Lee, 2003; Kewley et al., 2004; Lee, 2006). The expression 
of NPAS4 in a panel of normal adult and fetal tissue RNA was then investigated 
by semi-quantitative RT-PCR using exon-specific primers and NPAS4 was 






Table 3.2. Sequences of primers used in this study. Abbreviations: RT-PCR, 
reverse transcription PCR; MSP, methylation specific PCR; BGS, bisulfite genomic sequencing; 




Figure 3.2. mRNA expression, protein and exon structure and the CpG-rich 
promoter of NPAS4. (A) NPAS4 protein domain structure (not to scale). Location of the 
basic motif, bHLH, PAS, PAC and TAD domains are color-coded. Amino acid length is shown 
below bracket. (B) NPAS4 expression profile in normal human adult and fetal tissues by semi-
quantitative RT-PCR. The house-keeping gene GAPDH was used as loading control. Name of 
the gene assessed and size of the PCR product are shown on the left and right respectively. 
Abbreviations: S.M., skeletal muscle; B.M., bone marrow. (C) Exon structure of the human 
NPAS4 gene (not to scale). Numbered colored boxes represent corresponding exons and black 
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lines represent splicing. Location of primers used in 5'-RNA ligase mediated rapid amplification 
of cDNA ends (RLM-RACE) are shown by thick black arrows. Size of the gene is shown below 
the bracket. (D) The CpG rich NPAS4 promoter. Promoter sequence, first exon and the locations 
of the MSP and BGS primers are shown. The first exon as defined in the GenBank sequence 
NM_178864 is shown in caps and individual CpG sites are shown in bold caps. Transcriptional 
start sites as determined by 5'-RLM-RACE in normal adult trachea RNA is marked with an 
arrowhead. MSP (NPAS4-M1/M2, U1/U2) and BGS (NPAS4-BGS7/8) primer locations are 
marked with thick arrows and double-underlined respectively. 
3.3.2 NPAS4 transcribes from a functional promoter and is autologously 
regulated 
To identify the functional promoter of NPAS4, 5'-RLM RACE was performed 
on normal human adult trachea RNA using antisense primers targeting NPAS4 
exons 4, 3 and 2 (Table 3.2 and Figure 3.2C) and the resulting PCR product was 
cloned and sequenced. Subsequent Basic Local Alignment Search Tool 
(BLAST) searches (Altschul et al., 1990) identified a transcriptional start site 
(TSS) 35bp away from the TSS of the GenBank reference sequence 
(NM_178864) for NPAS4 (Figure 3.2D). We then downloaded and analyzed the 
whole NPAS4 gene sequence together with 5 Kb upstream of the first exon and 
found a CpG island of 2,315 bp with 153 CpG sites encompassing part of the 
promoter, exon 1, intron 1 and part of exon 2 (Takai and Jones, 2003): GC 
content, 62.3%; observed/expected CpG ratio, 0.681 (Figure 3.2A, 3.3A and 
3.5A). Potential AP1, E2F, NK-κB, Sp1 and p53 binding sites on the NPAS4 
promoter were predicted and mapped by three transcription factor (TF) search 




Figure 3.3. Localization of the functional NPAS4 promoter. (A) NPAS4 promoter 
structure (Not to scale). Schematic diagram of the 2,810 bp NPAS4 5'-promoter and part of exon 
1 region is shown. Genomic sequence represented by horizontal line and blue boxes represent 
exons. TSS labeled with an arrow and potential AP1, E2F, NF-κB, Sp1 and p53 binding sites 
predicted by three different bioinformatics programs are labeled. Thick black bar denotes the 
location of the CpG island. (B) Functional localization of the NPAS4 promoter via promoter 
luciferase assays. Promoter luciferase activities of three different regions of the NPAS4 promoter 
relative to the promoter-less control vector are shown. Data from three-independent luciferase 
assays (± s.d) in HONE1, C666-1 and HCT116 cell lines. All promoter constructs are able to 
drive transcription of the target gene in all cell lines tested. (C) NPAS4 autologously regulates its 
own promoter. NPAS4 promoter construct pGL4-NPAS4-PF2/PR1(-2614/+196) was transfected 
into HCT116 and C666-1 cell lines with or without NPAS4 expression constructs (dark and light 
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grey bars respectively) and assayed for luciferase activities after 48h. Results of luciferase 
assays with respect to pGL4 plasmid control (black bars) in triplicates are shown in the 
histogram. All data shown are from three-independent luciferase assays (± s.d).  
 The NPAS4 promoter was next evaluated for functionality by cloning 
three fragments of differing length separately into the promoter-less luciferase 
construct pGL4 and transfected HONE1, C666-1 and HCT116 cell lines for 
promoter luciferase assays. All three NPAS4 promoter fragment lengths are able 
to drive transcription with the shortest (-639/+196bp) and largest (-
2614/+196bp) fragment showing the highest and lowest activity respectively 
(Figure 3.3B) thereby confirming the functionality of the NPAS4 promoter.  
 It was previously reported that NPAS4 autoregulate its own promoter 
activity in the SK-N-MC neuroblastoma cell line (Ooe et al., 2004) and we set 
off to re-confirm this finding. The longest NPAS4 promoter construct pGL4-
NPAS4-PF2/PR1(-2614/+196) with or without the NPAS4 expression construct 
were used to transfect C666-1 and HCT116 cell lines and assayed for luciferase 
activity. Co-transfection with the NPAS4 expression construct induced up-
regulation of luciferase activity by about 0.5 fold in C666-1 and 9 fold (Figure 
3.3C) in HCT116, thereby confirming the auto-regulatory function of NPAS4. 
3.3.3 NPAS4 is silenced by promoter CpG hypermethylation in multiple 
carcinoma cell lines 
NPAS4 is silenced in NPC HONE1 cells and this silencing may be reversed via 
Aza treatment. Together with the observation of a CpG island in its promoter, 
these suggest that promoter DNA hypermethylation may have a role to play in 
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NPAS4 silencing in NPC and possibly other carcinomas also. The expression of 
NPAS4 was examined in a panel of carcinoma cell lines using semi-quantitative 
RT-PCR and the expression status were correlated with its promoter CpG 
methylation using methylation-specific PCR (MSP) and bisulfite genomic 
sequencing (BGS). Data showed weak or no expression of NPAS4 mRNA in 
multiple carcinoma cell lines including 5/5 (100%) NPC, 2/2 (100%) colorectal, 
3/5 (60%) lung, 8/9 (89%) breast, 6/6 (100%) gastric and 12/16 (75%) 
esophageal carcinoma cell lines tested (Figure 3.4). In concordance with the 
view that promoter DNA methylation may be responsible for NPAS4 silencing, 
strong methylated alleles were consistently detected in cell lines without NPAS4 
expression (Figure 3.4 and Table 3.3). Interestingly, weak NPAS4 expression 
was detected in two normal cell lines (HEK293 and NP69) with no methylation 






Figure 3.4. Expression and promoter DNA methylation analysis of NPAS4 in multiple tumor cell lines and normal controls. NPC, colon, 
lung, breast, gastric and esophageal carcinoma cell lines; immortalized normal cell lines (HEK293, RHEK1, NE1, NE3 and NP69) as controls. Gene and PCR cycles assayed 




Table 3.3. NPAS4 methylation frequencies in cell lines and primary tumors 
studied. 
 Next, we performed high-resolution BGS analysis for 25 CpG sites 
(inclusive of those CpGs targeted by MSP primers) within a 468bp region in the 
NPAS4 promoter (Figure 3.5A) and the data obtained confirmed our MSP 
results (Figure 3.5B). Taken together, the data show that NPAS4 silencing is 
associated with aberrant promoter DNA hypermethylation and is a common 
event in multiple tumor types. 
 3.3.4 NPAS4 expression is restored upon pharmacological or genetic 
demethylation 
To assess again whether promoter DNA hypermethylation play a causal role in 
NPAS4 silencing, four cell lines (HCT116, HK1, C666-1 and HONE1) with 
methylated and silenced NPAS4 were treated with either the DNA 
methyltransferase (DNMT) inhibitor 5-aza-2'-deoxycitidine (Aza) or the histone 
deacetylase (HDAC) inhibitor trichostatin A (TSA) or a sequential treatment of 
Aza for three days before TSA treatment for another 24h. NPAS4 expression 
was restored after Aza treatment but at different levels, together with a 
concomitant increase in the unmethylated allele detected via MSP (Figure 3.5C). 
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TSA treatment alone generally failed to induce NPAS4 re-expression except in 
C666-1; implying a critical role for DNA methylation in NPAS4 silencing 
(Figure 3.5C). Sequential treatment with Aza and TSA had a synergistic effect 
on NPAS4 expression in HCT116 and C666-1 cells with a strong increase in the 
unmethylated alleles as assessed by MSP (Figure 3.5C). BGS data further 
confirmed the demethylation of the NPAS4 promoter (Figure 3.5B).  
 
Figure 3.5. NPAS4 is silenced in multiple carcinoma cell lines via promoter 
DNA hypermethylation and demethylation induced by pharmacological or 
genetic approaches could induce the re-expression of NPAS4. (A) Schematic 
diagram of the 960 bp fragment of the NPAS4 promoter and exon 1 showing the location of 71 
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CpG dinucleotides along a 960bp fragment. Each vertical line represents one CpG site. Location 
of the 25 CpG sites assayed via MSP and BGS analysis are demarcated by the horizontal bracket. 
Gray arrows indicate the location of MSP primers. Arrow denotes the TSS and box represents 
exon one of NPAS4. (B) High resolution mapping of individual CpG sites on the NPAS4 
promoter in tumor and normal cell lines as assessed by BGS. A 468 bp fragment of the NPAS4 
core promoter containing 25 CpG sites was analyzed using BGS and dideoxynucleotide 
sequencing. CpG number is shown in ballooned arrows on top and gray arrows indicate MSP 
primers location. Individual CpG methylation status is expressed as percentage methylation 
calculated from 5-12 sequenced colonies. MSP and RT-PCR results are shown on the right. (C) 
Demethylation by Aza restores NPAS4 expression in Aza-treated cell lines with concomitant 
demethylation of its promoter. (D) Genetic double knock-out of both DNMT1 and DNMT3B 
strongly induces NPAS4 promoter demethylation and mRNA expression. (E) High-resolution 
BGS methylation mapping of the NPAS4 promoter verified the genetic demethylation in 
HCT116-DKO cell line. Schematic diagram of the 468bp promoter fragment analyzed by BGS 
with short vertical lines representing each CpG site. Percentage methylation calculated from 5-
12 randomly sequenced colonies. MSP and RT-PCR results shown on the right and locations of 
MSP primers indicated by thick grey arrows. M, methylated; U, unmethylated; +, expressed; -, 
silenced.   
 NPAS4 expression could also be re-activated by genetic demethylation 
induced through the knock-out (KO) of DNMT3B (3BKO cell line) but a strong 
re-expression and increase in the unmethylated allele was observed with the KO 
of both DNMT1 and DNMT3B (DKO cell line) (Rhee et al., 2002) (Figure 3.5D). 
This strong re-expression of NPAS4 was accompanied with a dramatic reversal 
of the previously dense DNA methylation as verified via high-resolution BGS 
analysis (Figure 3.5E). These results indicate that transcriptional silencing of 




3.3.5 Frequent NPAS4 methylation observed in primary tumors 
Having established that promoter DNA hypermethylation directly affect the 
expression of NPAS4 in tumor cell lines, we asked whether this phenomenon 
may be observed in primary tumors too. NPAS4 was found to be methylated 
frequently in 100% (21/21) of primary NPC, 85.7% (42/49) of esophageal, 94.4% 
(17/18) of gastric and 94.7% (18/19) of breast tumors (Figure 3.6 and Table 3.3). 
These results indicate that NPAS4 methylation is a common event in multiple 
tumors. 
 
Figure 3.6. Promoter DNA hypermethylation of NPAS4 in multiple primary 
carcinomas. MSP data showing NPAS4 promoter DNA methylation in multiple primary 
carcinomas. M, methylated; U, unmethylated. 
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3.3.6 NPAS4 is an indirect TP53 target gene and up-regulated in response 
to DNA damage  
As the 11q13 TS CR was found to be deleted after gamma irradiation 
(Mendonca et al., 1999; Mendonca et al., 2004), we hypothesized that this 
region may be involved in suppression of the tumor phenotype after DNA 
damage. Cell lines (HEK293, 293-T, NP69, HCT116 and C666-1) were treated 
with 0.5µg/ml of adriamycin for 24h before RNA extraction and RT-PCR 
analysis for NPAS4 together with cyclin-dependent kinase inhibitor 1 (CDKN1A) 
as positive control for DNA damage. Data showed that both NPAS4 and 
CDKN1A are up-regulated after drug treatment (Figure 3.7A). Next we traced 
the up-regulation of NPAS4 in cell lines after 1µg/ml adriamycin (HEK293, 
293-T, HCT116, C666-1 and HONE1) or 30J/m2 of Ultra-Violet (UV) light 
(HCT116 and HCT116/p53KO) treatment in a time-course experiment (6h, 10h 
and 24h) and results showed consistent up-regulation of NPAS4 with the 
strongest expression at 24h (Figures 3.7B and 3.7C); suggesting NPAS4 may be 
involved in the DNA damage response.  
 As the tumor suppressor TP53 is critically involved in the DNA damage 
response (Efeyan and Serrano, 2007; Yu et al., 1999), we asked whether TP53 
have a role in the up-regulation of NPAS4 after DNA damage. HCT116 and the 
TP53-null HCT116/p53KO cells were treated with either adriamycin (1µg/ml) 
or UV (30J/m2) before real-time PCR analysis. Data showed that CDKN1A 
exhibited a typical TP53-dependent up-regulation in HCT116 versus 
HCT116/p53KO cells 24h post-treatment (7- and 3.5-fold increase in 
Adriamycin and UV treatment respectively versus 1.5- and 2-fold) (Figure 3.7C, 
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right panel). NPAS4 showed an expression pattern similar to CDKN1A following 
UV treatment in HCT116 cells (6-fold increase versus 2-fold in 
HCT116/p53KO) (Figure 3.7C, left panel). However this pattern is reversed in 
Adriamycin treated cells with NPAS4 induction in HCT116/p53KO almost 
doubled that observed in HCT116 (20-fold versus 10-fold) (Figure 3.7C, left 
panel). These data suggest that TP53 may have variable effect on NPAS4 




Figure 3.7. NPAS4 expression is induced by DNA damage treatments and is 
indirectly regulated by the TP53 tumor suppressor. (A) NPAS4 is up-regulated in 
Adriamycin treated cells. Cells lines were treated with or without 0.5µg/ml of Adriamycin for 
24h and assessed for NPAS4 expression. (B) Time-course experiment on cell line using 1µg/ml 
 91 
 
Adriamycin treatment for 6, 10 and 24h. (C) Real-Time PCR analysis on NPAS4 (left panel) and 
CDKN1A (right panel) in HCT116 and HCT116/p53KO cells after 6, 10 and 24h of treatment 
with 1µg/ml adriamycin (top panel) or 30J/m2 UV irradiation (bottom panel). Fold-induction is 
shown normalized to control samples at 0h. Experiments were performed in triplicates and error 
bars indicated standard deviation. (D) Schematic diagram of 8 putative p53 binding site 
locations on the NPAS4 promoter (+2,000bp) and gene (5,704bp). (E) NPAS4 is an indirect 
target of TP53. ChIP analysis on HCT116 cells show TP53 does not bind to NPAS4 promoter 
after Adriamycin or UV treatment. ChIP assay was performed on sonicated chromatin generated 
from HCT116 cells with/without 1µg/ml Adriamycin (left panel) or 30J/m2 UV irradiation (right 
panel). Input chromatin represents a 1% portion of the sonicated chromatin before 
immunoprecipitation. Samples were immunoprecipitated with either rabbit IgG or anti-p53 
antibody before PCR amplification. ChIP for CDKN1A was used as positive control for TP53 
binding. Rabbit IgG was used as a negative control. Primer sequences and fragment size are 
available in Table 3.2. 
 To determine whether NPAS4 is a direct target for TP53, we performed 
chromatin immunoprecipitation (ChIP) analysis on HCT116 cells after treatment 
with either Adriamycin or UV light to assess TP53 binding to the NPAS4 gene. 
The entire NPAS4 gene together with 5,000bp upstream of the first exon was 
interrogated via bioinformatics and eight putative TP53 binding sites were 
identified and primers were designed targeting each site (Figure 3.7D and 
primer sequences in Table 3.2). Subsequent ChIP analysis revealed that TP53 
did not bind any of these sites whereas selective enrichment of the TP53 binding 
site in the CDKN1A gene was observed for both treatments (Figure 3.7E). Taken 
together, our data suggest that NPAS4 is functionally involved in the cellular 




3.3.7 NPAS4 inhibits tumor cell clonogenicity, proliferation and migration 
The fact that NPAS4 is frequently silenced in multiple tumor cell lines and 
primary tumors suggest that it is likely to function as a tumor suppressor. We 
examined the effect of ectopic NPAS4 expression on tumor cell clonogenicity by 
transfecting the NPAS4 expression construct (pcDNA3.1(+)-NPAS4) into NPC 
and colorectal carcinoma cell lines HONE1 and HCT116. These cell lines were 
selected based on their silenced or significantly reduced NPAS4 expression 
status and TP53 expression construct was used in tandem as positive control. 
Ectopic expression of NPAS4 drastically reduced the colony formation ability of 
HONE1 and HCT116 to 51% (P < 0.05) and 28% (P < 0.01) respectively in 
monolayer culture compared to empty vector control (Figure 3.8A and 3.8B); 




Figure 3.8. Forced re-
expression of NPAS4 
strongly inhibited cell 
clonogenicity, growth 
and migration. (A) Ectopic 
expression of NPAS4 greatly 
inhibited clonogenicity of 
HONE1 and HCT116. NPC 
HONE1 and colorectal 
carcinoma HCT116 cell lines 
were transfected with empty 
vector, TP53 and NPAS4 
expression constructs and 
selected with G418. Control 
cells with no vector would not survive G418 selection. (B) Quantitative analyses of colony numbers of HONE1 and HCT116. Values are the mean ±s.e. from three 
independent experiments. Asterisk indicates statistically significant difference (*P < 0.05, **P<0.01). (C) NPAS4 expression in HONE1 stable transfectant by RT-PCR. (D) 
Growth curves of HONE1 cells assayed via MTT assays after transfection with either NPAS4 expression vector or control vector. The mean of triplicate experiments are 
plotted at various timepoints. (*P < 0.016).  (E) Stable NPAS4 expression inhibits the migration of HONE1 cells. Representative scratch wound healing assay result. Photos 
were taken at different time points after the scratch.  
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 To further characterize the function of NPAS4, we examined the effect 
of NPAS4 on cell proliferation and migration by generating stably NPAS4 and 
empty vector transfected cells by G418 selection over two weeks and tested for 
NPAS4 expression via RT-PCR(Figure 3.8C). Cell proliferation rate was then 
tracked over a 96h period with readings collected every 24h in triplicates and. 
measured using the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium 
bromide (MTT) assay. Stably transfected HONE1/NPAS4-c3 cells showed a 34% 
reduction (P < 0.016) in cell proliferation rate compared to the empty vector 
stably transfected HONE1/pcDNA3.1+ cells (Figure 3.8D). In addition, the 
effect of NPAS4 expression on HONE1 cell motility was also assessed by 
scratch wound healing assay. NPAS4 expressing HONE1/NPAS4-c3 cells 
spread along the wound edges significantly slower than the vector transfected 
HONE1/pcDNA3.1+ cells at 24h (Figure 3.8E). Taken together, NPAS4 
expression inhibits tumor cell clonogenicity, proliferation and migration. 
3.4 Discussion 
One of the most common event in all human tumors is chromosomal aberrations. 
Previous studies have demonstrated the existence of a tumor suppressive CR 
within chromosome 11q13 in NPC and other tumors (Chakrabarti et al., 1998; 
Cheng et al., 2000; Cheng et al., 2002; Hui et al., 1996; Lung et al., 2008; 
Sirchia et al., 2000; Srivatsan et al., 2002; Venugopalan et al., 1998; Zhuang et 
al., 1995). Detailed molecular genetics analysis in NPC localized the tumor 
suppressive CR to a 1.8 Mb region (flanked by the markers D11S4907 and 
GSTP1); other groups working on the same region in cervical cancer suggested 
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the TSG/s to be involved in transcriptional regulation (Cheng et al., 2002). 
However to date, no TSG/s candidate relevant in NPC has been identified.  
 In this study we provide evidence that support NPAS4 as a strong 
candidate TSG that may be relevant in NPC and other tumors. NPAS4 is located 
within the 11q13 TS CR and was the only one silenced transcriptionally in a 
panel of 10 putative/confirmed transcriptional regulators identified from 68 
genes within this region. This gene was found to be expressed ubiquitously in all 
normal adult and fetal tissues examined and transcribed from a functional 
promoter. The NPAS4 CpG-rich promoter was additionally found to be 
hypermethylated in multiple tumor types including NPC, colorectal, lung, breast, 
gastric and esophageal carcinoma cell lines and primary tumors. This dense 
promoter methylation was observed to have a causal role in the transcriptional 
silencing of NPAS4 and could be reversed via pharmacological treatment with 
Aza or genetic double knockout of DNMT1 and DNMT3B. The frequent 
deregulation of NPAS4 strongly suggests that it may be an important tumor 
suppressor. NPAS4 was also found to be transcriptionally up-regulated after 
DNA damage treatments suggesting that it might have a role in DNA damage 
and that it may be an indirect target of the known tumor suppressor TP53. 
Forced expression of NPAS4 in carcinoma cell lines inhibited tumor cell 
clonogenicity, proliferation and migration, lending further support to the 
candidate tumor suppressor role of NPAS4.  
 NPAS4 was not suggested to be a candidate TSG in cervical carcinoma 
due to it being highly expressed in HeLa and three other cervical carcinoma cell 
lines (data not shown). However an alternative inactivation mechanism like 
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DNA mutation may be involved in cervical carcinoma and further work is 
required to elucidate a possible role for NPAS4 in cervical cancer. In addition, 
previous studies in human, rat and mouse tissues using Northern blots have 
reported strong NPAS4 expression only in the brain and weak expression in 
skeletal muscle, kidney and testis (Moser et al., 2004; Ooe et al., 2004; Shamloo 
et al., 2006). This is in direct contrast to our data which showed NPAS4 
expression in all normal human adult and fetal tested; which should be a 
discrepancy due to the different method used with semi-quantitative RT-PCR 
being much more sensitive than Northern blots. Our data is further supported 
using primers designed to target different sites on the NPAS4 mRNA (data not 
shown). 
 Methylation of NPAS4 promoter DNA was observed in the immortalized 
normal RHEK1 cell line and expression was down-regulated in HEK293 and 
NP69 cell lines but with no DNA methylation observed. This interesting 
phenomenon may suggest that NPAS4 silencing probably occurs early in 
tumorigenesis and that histone modifications may play a role in NPAS4 
silencing and precede DNA methylation. Indeed it was found that in cancer cells, 
many of the promoter hypermethylated cancer genes were enriched in the 
repressive form of histone (di- and tri-methylated H3K9 and tri-methylated 
H3K27) (Ohm et al., 2007; Ohm and Baylin, 2007). In addition, studies in 
embryonic cancer cells suggested that the stem cell chromatin state in these cells 
may enhance promoter CpG hypermethylation of key TSGs, encouraging 
abnormal cell expansion and enhance subsequent tumor initiation and 
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progression (Ohm et al., 2007; Ohm and Baylin, 2007; Rodriguez-Paredes and 
Esteller, 2011). Further work is necessary to confirm this phenomenon. 
 The cellular DNA damage response is of utmost importance to the cell in 
order to pass on the genetic material intact and unchanged to the next generation 
(Jackson and Bartek, 2009; Lukas et al., 2011). NPAS4 is consistently up-
regulated after treatment with DNA damaging agents (adriamycin and UV 
irradiation) and hence is likely to have a role in the cellular DNA damage 
response. Our data further suggest that NPAS4 may be an indirect target of the 
important tumor suppressor TP53. This indirect effect on NPAS4 expression by 
TP53 is however variable and further investigation is required to answer 
conclusively the effect of TP53 on NPAS4 and the downstream functions. In 
addition as NPAS4 is a transcriptional regulator (Ooe et al., 2004), it is 
important to understand the downstream targets of NPAS4 especially in the 
context of the DNA damage response and our lab is working to understand this 
problem.  
 In summary, this is the first report identifying NPAS4 as a candidate 
tumor suppressor gene located within the 11q13 tumor suppressive critical 
region and relevant in NPC and multiple other tumors. NPAS4 possess tumor 
inhibitory properties and was further found to be silenced epigenetically in 
multiple tumor types. In addition, NPAS4 could play a role in the cellular DNA 
damage response and is an indirect TP53 target. The high frequency with which 
NPAS4 is silenced in multiple carcinomas suggests that it can be used as a 
potential epigenetic biomarker for these tumors. Though important questions 
like the downstream targets of NPAS4 after DNA damage and their functions 
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remain unanswered, our study identified a novel tumor suppressor gene 
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